Amedeo Smart

Free Medical Literature Service

 

Amedeo

Tuberculosis
  Free Subscription

Articles published in
Int J Tuberc Lung Dis
    April 2024
  1. PARREIRA PL, Fonseca AU, Soares F, Conte MB, et al
    Chest X-ray evaluation using machine learning to support the early diagnosis of pulmonary TB.
    Int J Tuberc Lung Dis. 2024;28:171-175.
    >> Share

  2. DOGO FM, Ate S, Agossou K, Menon S, et al
    Decentralising DOT for drug-susceptible TB from the health facilities to the community level in Togo.
    Int J Tuberc Lung Dis. 2024;28:195-201.
    >> Share

  3. ILAIWY G, Heysell SK, Lukumay S, Agustino D, et al
    Cash transfers to enhance completion of TB screening among household contacts in rural Tanzania.
    Int J Tuberc Lung Dis. 2024;28:176-182.
    >> Share

  4. MARKS SM, Winston CA
    Estimated treatment costs for multidrug-resistant TB in the United States.
    Int J Tuberc Lung Dis. 2024;28:214-215.
    >> Share

  5. KAWATSU L, Uchimura K, Schwalb A, Houben R, et al
    New perspectives on the secular trend in pulmonary TB in post-war Japan (1953-1980).
    Int J Tuberc Lung Dis. 2024;28:207-209.
    >> Share

  6. SHAIKH A, Sriraman K, Vaswani S, Shah I, et al
    SMaRT-PCR: sampling using masks and RT-PCR, a non-invasive diagnostic tool for paediatric pulmonary TB.
    Int J Tuberc Lung Dis. 2024;28:189-194.
    >> Share

    March 2024
  7. OTA M, Hirao S, Uchimura K
    Lower TB notification rates in later life in the same birth cohort, Japan, 1950-2020.
    Int J Tuberc Lung Dis. 2024;28:157-159.
    >> Share

  8. PONTALI E, Akkerman OW, Zenner D, Migliori GB, et al
    Post-TB lung disease: keep going beyond TB!
    Int J Tuberc Lung Dis. 2024;28:113-114.
    >> Share

  9. THEKKUR P, Thiagesan R, Nair D, Karunakaran N, et al
    Using timeliness metrics for household contact tracing and TB preventive therapy in the private sector, India.
    Int J Tuberc Lung Dis. 2024;28:122-139.
    >> Share

  10. SOUSA S, Santos S, Alves CM, Goncalves G, et al
    Impact of annual TB screening on stone quarry workers in high-incidence Portuguese municipalities.
    Int J Tuberc Lung Dis. 2024;28:136-141.
    >> Share

  11. THOMSON H, Baines N, Huisamen T, Koegelenberg CFN, et al
    A new understanding of clinical patterns in post-TB lung disease.
    Int J Tuberc Lung Dis. 2024;28:115-121.
    >> Share

  12. LEVER S, Akkerman OW, Dekkers BGJ
    Pancreatitis delays the absorption of first-line anti-TB drugs.
    Int J Tuberc Lung Dis. 2024;28:163-165.
    >> Share

  13. YAMKOVOY K, Self JL, Jenkins HE, Horsburgh CR, et al
    Patterns of TB transmission in the United States, 2011-2017.
    Int J Tuberc Lung Dis. 2024;28:154-156.
    >> Share

  14. REZAEE M, Azizi N, Danaei B, Davari A, et al
    TB and interstitial lung disease: a systematic review and meta-analysis.
    Int J Tuberc Lung Dis. 2024;28:130-135.
    >> Share

  15. RUDOLF F, Abate E, Moges B, Gomes VF, et al
    A structured 2-week follow-up visit in the cascade of care for TB increases case detection.
    Int J Tuberc Lung Dis. 2024;28:148-153.
    >> Share

  16. LEAVITT SV, Rodriguez CA, Bouton TC, Horsburgh CR, et al
    Outcomes for people with TB by disease severity at presentation.
    Int J Tuberc Lung Dis. 2024;28:142-147.
    >> Share

    February 2024
  17. SILVA DR, Santos AP, Visca D, Bombarda S, et al
    The potential for vaccines to aid the treatment of post-TB lung disease.
    Int J Tuberc Lung Dis. 2024;28:44-45.
    >> Share

  18. LONG R, Heffernan C, Lau A
    Emphasis on post-TB lung disease and other sequelae of TB is good but a public health approach to TB is morally ambitious???
    Int J Tuberc Lung Dis. 2024;28:1-3.
    >> Share

  19. FEKADU G, Wang Y, You JHS
    Cost-effectiveness of pretomanid-based regimen for highly drugresistant TB in a low-burden setting.
    Int J Tuberc Lung Dis. 2024;28:12-17.
    >> Share

  20. TURNER RD, Birring SS, Bothamley GH
    Measuring cough-related quality of life and cough frequency in pulmonary TB.
    Int J Tuberc Lung Dis. 2024;28:25-31.
    >> Share

  21. SHIN JE, Jeon D, Mok J, Yim JJ, et al
    Compliance with new drug use and the effect of discrepant drug susceptibility testing on MDR/RR-TB treatment.
    Int J Tuberc Lung Dis. 2024;28:18-24.
    >> Share

  22. DOLEZALOVA K, Kika V, Wallenfels J
    Increasing incidence of TB in a low burden TB country due to migration from Ukraine.
    Int J Tuberc Lung Dis. 2024;28:39-40.
    >> Share

  23. NIGHTINGALE ES, Feasey HRA, Khundi M, Soko RN, et al
    Community-level variation in TB testing history in Blantyre, Malawi.
    Int J Tuberc Lung Dis. 2024;28:32-38.
    >> Share

    January 2024
  24. YILDIRIM K, Bozkurt S, Basibuyuk HH, Coban AY, et al
    Anti-tuberculosis activity of morusin: a promising flavonoid from white mulberry.
    Int J Tuberc Lung Dis. 2024;28:37-41.
    >> Share

  25. KUMAR SR, Hissar SS, Ramesh PM, Shanmugam M, et al
    Ethambutol-induced optic neuropathy: should we mandate ophthalmic examination in TB treatment?
    Int J Tuberc Lung Dis. 2024;28:51-53.
    >> Share

  26. SURIE D, Sathyanarayanan MK, Lavanya J, Smith JP, et al
    Long-term follow-up of persons diagnosed with multidrug-resistant TB in Chennai, India, 2013-2020.
    Int J Tuberc Lung Dis. 2024;28:54-56.
    >> Share

  27. RICCARDI N, Antonello RM, Besozzi G, Tadolini M, et al
    Ten common myths about drug-susceptible TB.
    Int J Tuberc Lung Dis. 2024;28:61-64.
    >> Share

  28. DU Y, Gu J, Yang Y, Chen Y, et al
    Efficacy and safety of bicyclol for treating patients with antituberculosis drug-induced liver injury.
    Int J Tuberc Lung Dis. 2024;28:6-12.
    >> Share

  29. BEELER ASAY GR, Woodruff R, Sanderson DM, Fisher CF, et al
    Cost-effectiveness of expanded latent TB infection testing and treatment: Lynn City, Massachusetts, USA.
    Int J Tuberc Lung Dis. 2024;28:21-28.
    >> Share

  30. SCHILDKRAUT JA, Sloan D, Boeree MJ
    If you want to go far, go together: standardisation and data sharing in TB drug development.
    Int J Tuberc Lung Dis. 2024;28:3-5.
    >> Share

  31. HOUBEN RMGJ, McCaffrey T, Tiemersma EW, Khan PY, et al
    Estimating TB survival - mind the immortal-time gap.
    Int J Tuberc Lung Dis. 2024;28:65-66.
    >> Share

  32. YUAN S, Cui Y, Shang Y, Su F, et al
    Prevalence, temporal trends and risk factors of drug-resistant TB in Zibo, China, 2018-2021.
    Int J Tuberc Lung Dis. 2024;28:57-58.
    >> Share

  33. GEIGER K, Patil A, Bergman A, Budhathoki C, et al
    Exploring HIV disease indicators at MDR-TB treatment initiation in South Africa.
    Int J Tuberc Lung Dis. 2024;28:42-50.
    >> Share

  34. OLIVEIRA DA SILVA B, Salindri AD, Goncalves TO, Cunha EAT, et al
    The impact of sputum quality on Xpert positivity in active case-finding for TB.
    Int J Tuberc Lung Dis. 2024;28:29-36.
    >> Share

  35. TYUFEKCHIEVA M, Varleva T
    Monitoring TB infection in contact cases: the impact of the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2024;28:59-60.
    >> Share

    December 2023
  36. YANG H, Antwi S, Maranchick N, Dompreh A, et al
    Effect of HIV infection on plasma exposure to first-line TB drugs and target attainment in children.
    Int J Tuberc Lung Dis. 2023;27:931-937.
    >> Share

  37. MAKEK MJ, Trauer JM, Blackbourn HD
    Literature Highlights.
    Int J Tuberc Lung Dis. 2023;27:882-884.
    >> Share

  38. ARAUJO-PEREIRA M, Andrade BB
    Atorvastatin to reduce bacillary load and attenuate lung damage in TB patients.
    Int J Tuberc Lung Dis. 2023;27:880-881.
    >> Share

  39. COMMIESIE E, Stijnberg D, van den Boogaard J, Gopie F, et al
    Challenges and opportunities for TB elimination in Suriname.
    Int J Tuberc Lung Dis. 2023;27:946-948.
    >> Share

  40. RAGHEB SM, White JB, Jarand J, Fisher DA, et al
    Assessing patient satisfaction with video-supported therapy for drug-susceptible TB treatment.
    Int J Tuberc Lung Dis. 2023;27:938-940.
    >> Share

  41. CHUNG C, Jo KW, Shim TS
    Treatment outcome, recurrence and safety of multidrug-resistant TB treated with low-dose linezolid.
    Int J Tuberc Lung Dis. 2023;27:918-924.
    >> Share

  42. DU CROS P, Greig J, Alffenaar JC, Cross GB, et al
    Standards for clinical trials for treating TB.
    Int J Tuberc Lung Dis. 2023;27:885-898.
    >> Share

  43. ADEWOLE OO, Omotoso BA, Ogunsina M, Aminu A, et al
    Atorvastatin improves sputum conversion and chest X-ray severity score.
    Int J Tuberc Lung Dis. 2023;27:912-917.
    >> Share

  44. QUINCER EM, Lyland A, Onyango D, LaCourse SM, et al
    The effect of antenatal isoniazid preventive therapy on birth outcomes in Western Kenya.
    Int J Tuberc Lung Dis. 2023;27:906-911.
    >> Share

  45. NETO ERD, Matos TS, Ferreira ACF, Bezerra-Santos M, et al
    The impact of COVID-19 on TB care in Brazil.
    Int J Tuberc Lung Dis. 2023;27:941-943.
    >> Share

  46. MENDOZA-TICONA A, Mitnick CD, Obregon G, Alarcon V, et al
    Screening with GenoType((R)) MTBDRplus shortens the time to MDR-TB treatment initiation but does not change outcomes.
    Int J Tuberc Lung Dis. 2023;27:949-951.
    >> Share

  47. KIBIRIGE D, Andia-Biraro I, Olum R, Adakun S, et al
    Metabolic characterisation of adult Ugandan patients with TB and diabetes mellitus comorbidity.
    Int J Tuberc Lung Dis. 2023;27:944-945.
    >> Share

    November 2023
  48. EDWARDS S, Humbert T, Berdzuli N, Azzopardi-Muscat N, et al
    Tackling TB in Europe: treatment gaps and deteriorating treatment availability is undermining progress.
    Int J Tuberc Lung Dis. 2023;27:793-796.
    >> Share

  49. MARGINEANU I, Butnaru T, Gafar F, Baiceanu D, et al
    TB therapeutic drug monitoring - analysis of opportunities in Romania and Ukraine.
    Int J Tuberc Lung Dis. 2023;27:816-821.
    >> Share

  50. KATRAK S, Wang R, Barry P
    Costs of treating multidrug-resistant TB in California in 2022.
    Int J Tuberc Lung Dis. 2023;27:864-866.
    >> Share

  51. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
    A novel home-based method for preparing suspensions of anti-TB drugs.
    Int J Tuberc Lung Dis. 2023;27:810-815.
    >> Share

  52. INBARAJ LR, Rade K, Selvaraju S, Rao R, et al
    Mortality estimates of central nervous system TB in India.
    Int J Tuberc Lung Dis. 2023;27:876-877.
    >> Share

  53. FRITSCHI N, Vaezipour N, Buettcher M, Portevin D, et al
    Ratios from full blood count as markers for TB diagnosis, treatment, prognosis: a systematic review.
    Int J Tuberc Lung Dis. 2023;27:822-832.
    >> Share

    October 2023
  54. ANDREWS F, Welch S, Scandrett K, Kaur H, et al
    Outcomes of TB contact tracing and predictors of success: a 10-year retrospective cohort analysis in Birmingham, UK.
    Int J Tuberc Lung Dis. 2023;27:766-771.
    >> Share

  55. TRAUER JM, Tiberi S, Graham SM, Blackbourn HD, et al
    Literature Highlights.
    Int J Tuberc Lung Dis. 2023;27:721-723.
    >> Share

  56. NELSON KN, Shah NS, Cranmer LM, Vasudevan L, et al
    An effective vaccine is only the first step: the need to create and sustain demand for TB vaccines.
    Int J Tuberc Lung Dis. 2023;27:718-720.
    >> Share

  57. PUMA D, Geadas C, Calderon RI, Yuen CM, et al
    Active case-finding for TB among incarcerated women in Peru.
    Int J Tuberc Lung Dis. 2023;27:784-786.
    >> Share

  58. AKKERMAN OW, Dijkwel RDC, Kerstjens HAM, van der Werf TS, et al
    Isoniazid and rifampicin exposure during treatment in drug-susceptible TB.
    Int J Tuberc Lung Dis. 2023;27:772-777.
    >> Share

  59. CHIANG SS, Zeng C, Roman-Sinche B, Altamirano E, et al
    Adaptation and validation of a TB stigma scale for adolescents in Lima, Peru.
    Int J Tuberc Lung Dis. 2023;27:754-760.
    >> Share

  60. KIM JY, Koo B, Lim SY, Cha HH, et al
    A non-invasive, sensitive assay for active TB: combined cell-free DNA detection and FluoroSpot assays.
    Int J Tuberc Lung Dis. 2023;27:790-792.
    >> Share

  61. REKART ML, Aung A, Cullip T, Mulanda W, et al
    Household drug-resistant TB contact tracing in Tajikistan.
    Int J Tuberc Lung Dis. 2023;27:748-753.
    >> Share

  62. RAJAVARDHANA T, Koushik MR, Jayakumar C, Ramalingam P, et al
    Adherence to treatment on a daily-dose regimen for TB.
    Int J Tuberc Lung Dis. 2023;27:778-780.
    >> Share

  63. SINGH UB, Ray Y, Kanswal S, Sharma HP, et al
    Low rifampicin levels in plasma associated with a poor clinical response in patients with abdominal TB.
    Int J Tuberc Lung Dis. 2023;27:787-789.
    >> Share

  64. FRAZIER C, Nabity SA, Flood J
    Incidence of TB disease among persons who use drugs in California.
    Int J Tuberc Lung Dis. 2023;27:781-783.
    >> Share

  65. RAJENDRAN P, Saini S, Kumar N, Vashistha H, et al
    Establishing proof of concept for utility of Trueprep((R))-extracted DNA in line-probe assay testing.
    Int J Tuberc Lung Dis. 2023;27:742-747.
    >> Share

    September 2023
  66. MACHAVARIANI E, Nonyane BAS, Lebina L, Mmolawa L, et al
    Perceived stigma among people with TB and household contacts.
    Int J Tuberc Lung Dis. 2023;27:675-681.
    >> Share

  67. VILJOEN L, Acaba J, Agbassi YJP, Beko B, et al
    Community perspective on child-friendly medications for drug-resistant TB: importance, priorities and advocacy.
    Int J Tuberc Lung Dis. 2023;27:655-657.
    >> Share

  68. RODRIGUEZ CA, Leavitt SV, Bouton TC, Horsburgh CR, et al
    Survival of people with untreated TB: effects of time, geography and setting.
    Int J Tuberc Lung Dis. 2023;27:694-702.
    >> Share

  69. BECKER GL, Amuge P, Ssebunya R, Motevalli M, et al
    Predictors of mortality in Ugandan children with TB, 2016-2021.
    Int J Tuberc Lung Dis. 2023;27:668-674.
    >> Share

  70. DO NASCIMENTO DR, Serpa SF, Bezerra-Santos M, do Carmo RF, et al
    The impact of the COVID-19 pandemic on TB diagnosis in the Brazilian prison population, 2020-2021.
    Int J Tuberc Lung Dis. 2023;27:688-693.
    >> Share

  71. GALEA JT, Chu AL, Sweetland AC, Jimenez J, et al
    Latent TB and depressive symptoms in household contacts of persons with active TB.
    Int J Tuberc Lung Dis. 2023;27:682-687.
    >> Share

    August 2023
  72. SILVA DR, Munoz-Torrico M, Fernandes GR, Narvaez-Diaz L, et al
    Isoniazid-resistant TB: treatment outcomes and impact of regimens with fluoroquinolones.
    Int J Tuberc Lung Dis. 2023;27:638-640.
    >> Share

  73. AHMED S, Lotia-Farrukh I, Khan PY, Adnan S, et al
    High prevalence of multidrug-resistant TB among household contacts in a high burden setting.
    Int J Tuberc Lung Dis. 2023;27:646-648.
    >> Share

  74. CHIANG SS, Graham SM, Schaaf HS, Marais BJ, et al
    Clinical standards for drug-susceptible TB in children and adolescents.
    Int J Tuberc Lung Dis. 2023;27:584-598.
    >> Share

  75. MAKEK MJ, Amorim GGC, Ragonnet R, Blackbourn HD, et al
    Literature Highlights.
    Int J Tuberc Lung Dis. 2023;27:581-583.
    >> Share

  76. ACUNA-VILLAORDUNA C, Jacobson KR, Horsburgh CR, Canning M, et al
    Initial experience with BPaL-based regimens to treat multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:649-650.
    >> Share

  77. HACKER B, Breuer C, Priwitzer M, Otto-Knapp R, et al
    TB screening of Ukrainian refugees in Germany.
    Int J Tuberc Lung Dis. 2023;27:641-642.
    >> Share

  78. HONGPRASIT P, Sonthisombat P
    Assessment of TB treatment adherence using computer-assisted self-interviewing.
    Int J Tuberc Lung Dis. 2023;27:626-631.
    >> Share

  79. RIKHOTSO MC, Ledwaba SE, Ngandu JK, Mavumengwana V, et al
    Favourable outcomes in RR-TB patients using BPaL and other WHO-recommended second-line anti-TB drugs.
    Int J Tuberc Lung Dis. 2023;27:599-605.
    >> Share

  80. MARITZ ER, Montepiedra G, Mitchell CD, Madhi SA, et al
    Predictors of TB disease in HIV-exposed children from Southern Africa.
    Int J Tuberc Lung Dis. 2023;27:619-625.
    >> Share

  81. CHIBOLELA M, de Haas P, Klinkenberg E, Kosloff B, et al
    Use of stool swabs in molecular transport media increases access to Xpert Ultra testing for TB in children.
    Int J Tuberc Lung Dis. 2023;27:612-618.
    >> Share

  82. HABIB SS, Uzair M, Dhanwani A, Sohail K, et al
    A model for integrating social protection measures with TB control in Pakistan.
    Int J Tuberc Lung Dis. 2023;27:651-652.
    >> Share

  83. RACHOW A, Ivanova O, Bakuli A, Khosa C, et al
    Performance of spirometry assessment at TB diagnosis.
    Int J Tuberc Lung Dis. 2023;27:850-857.
    >> Share

  84. SALERNO MM, Burzynski J, Mangan JM, Hill A, et al
    Adverse events among persons with TB using in-person vs. electronic directly observed therapy.
    Int J Tuberc Lung Dis. 2023;27:833-840.
    >> Share

  85. OWOLABI OA, Sillah AK, Loum I, Touray A, et al
    Factors associated with presenting to private sector care providers at the onset of TB symptoms.
    Int J Tuberc Lung Dis. 2023;27:867-868.
    >> Share

  86. SILVESTRE CR, Cavaco M, Afonso R, Alves S, et al
    TB infection in healthcare workers - the reality of a Portuguese hospital.
    Int J Tuberc Lung Dis. 2023;27:874-875.
    >> Share

  87. CHO MM, Kim HW, Kim JS, Min J, et al
    TB in ageing populations: lessons from Japan and Korea.
    Int J Tuberc Lung Dis. 2023;27:869-871.
    >> Share

    July 2023
  88. NUR N, Sharif AB, Mitra DK
    Stress resilience in patients with drug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:551-556.
    >> Share

  89. OKOYA F, Huang CC, Zhang Z, Lecca L, et al
    Culture-negative TB: clinical characteristics, risk factors and treatment outcomes.
    Int J Tuberc Lung Dis. 2023;27:557-563.
    >> Share

  90. ESCALANTE P, Vadiyala MR, Pathakumari B, Marty PK, et al
    New diagnostics for the spectrum of asymptomatic TB: from infection to subclinical disease.
    Int J Tuberc Lung Dis. 2023;27:499-505.
    >> Share

  91. STRAUSS M, Wademan DT, Mcinziba A, Hoddinott G, et al
    TB preventive therapy preferences among children and adolescents.
    Int J Tuberc Lung Dis. 2023;27:520-529.
    >> Share

  92. HARRIES AD, Lin Y, Thekkur P, Nair D, et al
    Why TB programmes should assess for comorbidities, determinants and disability at the start and end of TB treatment.
    Int J Tuberc Lung Dis. 2023;27:495-498.
    >> Share

  93. GLOGOWSKA A, Przybylski G, Bukowski J, Dolska E, et al
    TB and COVID-19 co-infection in a pulmonology hospital.
    Int J Tuberc Lung Dis. 2023;27:574-576.
    >> Share

  94. FERRARESE M, Antonello RM, Torri S, Saderi L, et al
    Extrapulmonary TB: a 30-year observational study of an Italian cohort.
    Int J Tuberc Lung Dis. 2023;27:564-566.
    >> Share

  95. WADEMAN DT, Viljoen L, Jacobs S, Meyerson K, et al
    Children s priorities to improve the acceptability of MDR-TB treatment: qualitative data from South Africa.
    Int J Tuberc Lung Dis. 2023;27:543-550.
    >> Share

  96. SINGH KP, Carvalho ACC, Centis R, D Ambrosio L, et al
    Clinical standards for the management of adverse effects during treatment for TB.
    Int J Tuberc Lung Dis. 2023;27:506-519.
    >> Share

  97. MARQUES J, Rocha JV, Soares P, Leite A, et al
    The effect of TB patient delay on loss to follow-up in Portugal.
    Int J Tuberc Lung Dis. 2023;27:537-542.
    >> Share

  98. CENTENO HURTADO KT, Garcia Bohorquez DF, Ruiz Gonzalez CE, Masias Leon Y, et al
    The burden of chronic obstructive pulmonary disease among hospitalised women in a developing country.
    Int J Tuberc Lung Dis. 2023;27:530-536.
    >> Share

  99. VENGURLEKAR D, Walker C, Mahajan R, Dalal A, et al
    Linezolid resistance in patients with drug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:567-569.
    >> Share

  100. ZUREIGAT H, Alhusban M, Nawaiseh M, Alomari L, et al
    Steps towards TB elimination in Jordan.
    Int J Tuberc Lung Dis. 2023;27:576-577.
    >> Share

    June 2023
  101. DE VRIES G, Akkerman O, Boeree M, van Hest R, et al
    Diagnosis, treatment and transmission of rifampicin-resistant TB in the Netherlands, 2010-2019.
    Int J Tuberc Lung Dis. 2023;27:471-477.
    >> Share

  102. MALHOTRA A, Mukiibi J, Kitonsa PJ, Nalutaaya A, et al
    Higher yield using an event-based vs. door-to-door approach for active case-finding for TB.
    Int J Tuberc Lung Dis. 2023;27:484-486.
    >> Share

  103. MAKEK MJ, Tiberi S, Felker I, Amorim GGC, et al
    Literature Highlights.
    Int J Tuberc Lung Dis. 2023;27:429-431.
    >> Share

  104. NI N, Wang N, Veronese V, Wang MZ, et al
    Current status and future prospects of TB digital treatment adherence technology use in China.
    Int J Tuberc Lung Dis. 2023;27:438-443.
    >> Share

  105. KIM SH, Yoo JY, Cho HS, Kim SR, et al
    Clinical and imaging features of drug-susceptible and multidrug-resistant TB in Korean adults.
    Int J Tuberc Lung Dis. 2023;27:487-489.
    >> Share

  106. LOUIE JK, Keh C, Agraz-Lara R, Phillips A, et al
    Highlighting the characteristics of TB disease in older people.
    Int J Tuberc Lung Dis. 2023;27:478-480.
    >> Share

  107. SUNG J, Musinguzi A, Kadota JL, Baik Y, et al
    Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda.
    Int J Tuberc Lung Dis. 2023;27:458-464.
    >> Share

  108. OESER C, Rangaka MX, Abubakar I
    Digital approaches to reducing TB treatment loss to follow-up.
    Int J Tuberc Lung Dis. 2023;27:432-437.
    >> Share

  109. RICH ML, Khan U, Zeng C, LaHood A, et al
    Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications.
    Int J Tuberc Lung Dis. 2023;27:451-457.
    >> Share

  110. MYERS B, Carney T, Rooney J, Malatesta S, et al
    Smoked drug use in patients with TB is associated with higher bacterial burden.
    Int J Tuberc Lung Dis. 2023;27:444-450.
    >> Share

  111. OTAALO B, Cevik M, Mwebesa E, Nabisere-Arinaitwe R, et al
    Prevalence of COVID-19 infection in TB clinics in Kampala, Uganda.
    Int J Tuberc Lung Dis. 2023;27:481-483.
    >> Share

    May 2023
  112. GUNTHER G, Guglielmetti L, Leu C, van Leth F, et al
    Relative cost of multidrug-resistant TB medicines in Europe.
    Int J Tuberc Lung Dis. 2023;27:341-344.
    >> Share

  113. KWARA A, Yang H, Martyn-Dickens C, Enimil A, et al
    Adequacy of WHO weight-band dosing and fixed-dose combinations for the treatment of TB in children.
    Int J Tuberc Lung Dis. 2023;27:401-407.
    >> Share

  114. GIRIDHARAN P, Devaleenal B, Thiruvengadam K, Kaleeswari M, et al
    A novel method for contact tracing for TB at household and community level.
    Int J Tuberc Lung Dis. 2023;27:414-415.
    >> Share

  115. SADERI L, Cabibbe AM, Puci M, Di Lorenzo B, et al
    A systematic review of the costs of diagnosis for multidrug-resistant/extensively drug-resistant TB in different settings.
    Int J Tuberc Lung Dis. 2023;27:348-356.
    >> Share

  116. GERIC C, Qin ZZ, Denkinger CM, Kik SV, et al
    The rise of artificial intelligence reading of chest X-rays for enhanced TB diagnosis and elimination.
    Int J Tuberc Lung Dis. 2023;27:367-372.
    >> Share

  117. FAJER EB, Costa FD, Pelissari DM, Diaz Quijano FA, et al
    Use of rapid molecular TB diagnostics for incarcerated people in Brazil.
    Int J Tuberc Lung Dis. 2023;27:416-418.
    >> Share

  118. KASWASWA K, Mlauzi L, Mpunga J, Mandambwe C, et al
    Use of local data to evaluate TB contact investigation in Malawi.
    Int J Tuberc Lung Dis. 2023;27:408-410.
    >> Share

  119. TANG J, Tang Z, Feng C, Tang Q, et al
    Efficacy and safety of video-assisted thoracoscopic surgery for pulmonary TB.
    Int J Tuberc Lung Dis. 2023;27:387-394.
    >> Share

  120. MAUGANS C, Loveday M, Hlangu S, Waitt C, et al
    Best practices for the care of pregnant people living with TB.
    Int J Tuberc Lung Dis. 2023;27:357-366.
    >> Share

  121. TAGUIBAO C, Lailo JM, Neukom J, Gones V, et al
    Digital survey results on pharmacy access to fixed-dose combination drugs for TB in Indonesia.
    Int J Tuberc Lung Dis. 2023;27:422-424.
    >> Share

  122. MOE S, Rekart ML, Hernandez D, Sholpan A, et al
    Primary bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Int J Tuberc Lung Dis. 2023;27:381-386.
    >> Share

  123. AHMED R, Osman N, Noory B, Osman R, et al
    Prevalence and determinants of chronic respiratory diseases in adults in Sudan.
    Int J Tuberc Lung Dis. 2023;27:373-380.
    >> Share

  124. PAREDES JL, Picon V, Reynolds L, Ugarte-Gil C, et al
    Impact of the COVID-19 pandemic on TB care in Peru.
    Int J Tuberc Lung Dis. 2023;27:411-413.
    >> Share

  125. MUTEMBA CM, Schindele A, Munyangaju I, Ramanlal N, et al
    Contribution of Xpert((R)) MTB/RIF to pediatric TB diagnosis in Mozambique.
    Int J Tuberc Lung Dis. 2023;27:419-421.
    >> Share

    April 2023
  126. GRIJOTA-CAMINO MD, Perez-Recio S, Trapero C, Luque MJ, et al
    Identifying gaps in the cascade of care for latent TB infection in a low-incidence setting.
    Int J Tuberc Lung Dis. 2023;27:315-321.
    >> Share

  127. VELEN K, Nguyen TA, Pham CD, Le HT, et al
    The effect of medication event reminder monitoring on treatment adherence of TB patients.
    Int J Tuberc Lung Dis. 2023;27:322-328.
    >> Share

  128. BOLHUIS MS, Akkerman OW, Sturkenboom MGG, van Boven JFM, et al
    Bedaquiline exposure in people with drug-resistant TB treated for diabetes: analysis of two phase 2 trials.
    Int J Tuberc Lung Dis. 2023;27:335-337.
    >> Share

  129. GOLETTI D, Pisapia R, Fusco FM, Aiello A, et al
    Epidemiology, pathogenesis, clinical presentation and management of TB in patients with HIV and diabetes.
    Int J Tuberc Lung Dis. 2023;27:284-290.
    >> Share

  130. MIGLIORI GB, Blackbourn HD
    Post-TB lung disease - the rationale for a Clinical Statement.
    Int J Tuberc Lung Dis. 2023;27:243-244.
    >> Share

  131. CAMPBELL JR, Chan ED, Anderson LF, Bonnet M, et al
    Association of smoking and alcohol use with rifampin-resistant TB treatment outcomes.
    Int J Tuberc Lung Dis. 2023;27:338-340.
    >> Share

  132. SACHDEVA KS, Bhatnagar AK, Bhaskar A, Singla N, et al
    QTc prolongation with bedaquiline treatment for drug-resistant pulmonary TB in a programmatic setting.
    Int J Tuberc Lung Dis. 2023;27:329-331.
    >> Share

  133. KAZIBWE A, Kyazze AP, Ssekamatte P, Mutebi EI, et al
    TB infection in adults with diabetes mellitus in Uganda.
    Int J Tuberc Lung Dis. 2023;27:308-314.
    >> Share

  134. NIGHTINGALE R, Carlin F, Meghji J, McMullen K, et al
    Post-TB health and wellbeing.
    Int J Tuberc Lung Dis. 2023;27:248-283.
    >> Share

  135. MANGAN JM, Burzynski J, deCastro BR, Salerno MM, et al
    Challenges associated with electronic and in-person directly observed therapy during a randomized trial.
    Int J Tuberc Lung Dis. 2023;27:298-307.
    >> Share

  136. KINTU TM, Mwanahamisi BS, Muwanguzi M, Kyagambiddwa T, et al
    Unfavorable treatment outcomes among patients with drug-resistant TB in Uganda.
    Int J Tuberc Lung Dis. 2023;27:291-297.
    >> Share

    March 2023
  137. COLA JP, Nascimento do Prado T, Alves KBA, Lapa E Silva JR, et al
    Factors associated with non-completion of TB preventive treatment in Brazil.
    Int J Tuberc Lung Dis. 2023;27:215-220.
    >> Share

  138. HUDDART S, Asege L, Jaganath D, Golla M, et al
    Continuous cough monitoring: a novel digital biomarker for TB diagnosis and treatment response monitoring.
    Int J Tuberc Lung Dis. 2023;27:221-222.
    >> Share

  139. YAACOUB H, Farhat AM, Najjar-Pellet J, Zgheib J, et al
    Planning for TB elimination in Lebanon.
    Int J Tuberc Lung Dis. 2023;27:171-174.
    >> Share

  140. KWON YS, Jang JG, Lee J, Choi KJ, et al
    Risk factors for peripheral neuropathy in patients on linezolid-containing regimens for drug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:232-234.
    >> Share

  141. PALACIOS CF, Hough MA, Shrestha R, Moll AP, et al
    Perceived stigma related to TB preventive therapy.
    Int J Tuberc Lung Dis. 2023;27:209-214.
    >> Share

  142. AKKERMAN OW, van Het Hof S, de Vries G, van Crevel R, et al
    Characteristics and mortality of central nervous system TB in the Netherlands: a 15-year comparison with other forms of TB.
    Int J Tuberc Lung Dis. 2023;27:237-239.
    >> Share

  143. HUAROTO L, Huaman MA, Mugruza R, Ticona C, et al
    Active case-finding of pulmonary TB in an urban emergency department.
    Int J Tuberc Lung Dis. 2023;27:202-208.
    >> Share

  144. ADEWOLE OO, Omotoso BA, Ogunsina M, Aminu A, et al
    Atorvastatin accelerates Mycobacterium tuberculosis clearance in pulmonary TB: a randomised phase IIA trial.
    Int J Tuberc Lung Dis. 2023;27:226-228.
    >> Share

  145. MALIK AA, Jaswal M, Siddiqui S, Amanullah F, et al
    Role of symptom and chest X-ray screening in evaluating child household contacts for pulmonary TB.
    Int J Tuberc Lung Dis. 2023;27:235-236.
    >> Share

  146. TRAUER JM
    Targeted TB control in migrants to low-burden countries.
    Int J Tuberc Lung Dis. 2023;27:169-170.
    >> Share

  147. MARTINEZ-GARCIA MA, Guan WJ, de-la-Rosa D, Athanazio R, et al
    Post-TB bronchiectasis: from pathogenesis to rehabilitation.
    Int J Tuberc Lung Dis. 2023;27:175-181.
    >> Share

  148. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
    Stable, compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field.
    Int J Tuberc Lung Dis. 2023;27:189-194.
    >> Share

  149. DAMARAJU V, Singh N, Garg M, Kathirvel S, et al
    Effect of prior pulmonary TB on low-dose computed tomography during lung cancer screening.
    Int J Tuberc Lung Dis. 2023;27:223-225.
    >> Share

  150. SPRUIJT I, Erkens C, Greenaway C, Mulder C, et al
    Reducing the burden of TB among migrants to low TB incidence countries.
    Int J Tuberc Lung Dis. 2023;27:182-188.
    >> Share

  151. BAIK Y, Nakasolya O, Isooba D, Mukiibi J, et al
    Cost to perform door-to-door universal sputum screening for TB in a high-burden community.
    Int J Tuberc Lung Dis. 2023;27:195-201.
    >> Share

    February 2023
  152. CHUNG C, Shin JE, Jeon D, Kang H, et al
    Treatment outcomes and safety of bedaquiline, delamanid, and linezolid in multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:151-153.
    >> Share

  153. GOMES I, Garg T, Churchyard G, Gupta A, et al
    The cascade of care for household contacts of people with drug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:154-156.
    >> Share

  154. TOCHAENG C, Eksombatchai D, Boonsarngsuk V
    Factors associated with false-negative for T-SPOT.TB in patients with TB disease.
    Int J Tuberc Lung Dis. 2023;27:128-134.
    >> Share

  155. ALKABAB Y, Warkentin J, Cummins J, Katz B, et al
    Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus.
    Int J Tuberc Lung Dis. 2023;27:135-139.
    >> Share

  156. FORSMAN LD, Alffenaar JWC
    Diabetes mellitus and TB - finding strategies to reduce the double burden of disease.
    Int J Tuberc Lung Dis. 2023;27:91-93.
    >> Share

  157. BARKER M, Gunther A, Wurps H, Gebhardt A, et al
    Ultrasound-guided lymph node biopsy in smear-negative children and adolescents with suspected TB.
    Int J Tuberc Lung Dis. 2023;27:164-165.
    >> Share

  158. BOLSTERLI E, Keller PM, Suter-Riniker F, Kruger L, et al
    A comparison of bronchoalveolar lavage and gastric aspirate for diagnosis of paediatric TB.
    Int J Tuberc Lung Dis. 2023;27:148-150.
    >> Share

  159. VILLA S, Carugati M, Rubach MP, Cleaveland S, et al
    'One Health approach to end zoonotic TB.
    Int J Tuberc Lung Dis. 2023;27:101-105.
    >> Share

  160. BALTAS I, Sturdy A, Kavallieros K, McGregor A, et al
    Diabetes mellitus is not a predictor of poor TB treatment outcomes.
    Int J Tuberc Lung Dis. 2023;27:140-145.
    >> Share

  161. CHUKWUOGO O, Odume B, Ogbudebe C, Useni S, et al
    Strategic approach to optimisation of TB contact investigation in Nigeria.
    Int J Tuberc Lung Dis. 2023;27:161-163.
    >> Share

  162. PAUDEL K, Nalutaaya A, Robsky KO, Kitonsa PJ, et al
    The impact of time at home on potential yield of home-based TB contact investigation.
    Int J Tuberc Lung Dis. 2023;27:121-127.
    >> Share

  163. KOESOEMADINATA RC, McAllister SM, Soetedjo NNM, Santoso P, et al
    Diabetes characteristics and long-term management needs in diabetic TB patients.
    Int J Tuberc Lung Dis. 2023;27:113-120.
    >> Share

  164. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
    Extemporaneously compounded liquid formulations of clofazimine.
    Int J Tuberc Lung Dis. 2023;27:106-112.
    >> Share

  165. GENADE LP, Kahamba T, Scott L, Tempia S, et al
    Co-testing a single sputum specimen for TB and SARS-CoV-2.
    Int J Tuberc Lung Dis. 2023;27:146-147.
    >> Share

    January 2023
  166. KHAN U, Guglielmetti L
    Tailored TPT for drug-resistant TB - promoting equity and access to optimal care.
    Int J Tuberc Lung Dis. 2023;27:89b-90.
    >> Share

  167. MANSOOR H, Hirani N, Chavan V, Das M, et al
    Clinical utility of target-based next-generation sequencing for drug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:41-48.
    >> Share

  168. GILLESPIE SH
    Improving outcomes for multidrug-resistant TB: the role of integrated systems.
    Int J Tuberc Lung Dis. 2023;27:1-2.
    >> Share

  169. SEHGAL IS, Muthu V, Agarwal R
    Aspergillus infection is an important complication of post-TB bronchiectasis.
    Int J Tuberc Lung Dis. 2023;27:89a-89.
    >> Share

  170. OLARU ID, Beliz Meier M, Schumacher SG, Prodanovic N, et al
    Co-administration of treatment for drug-resistant TB and hepatitis C.
    Int J Tuberc Lung Dis. 2023;27:66-68.
    >> Share

  171. FELKER I, Trajman A
    Shorter regimens for multidrug-/rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:3-4.
    >> Share

  172. KWON YS, Shin JE, Kang H, Jeon D, et al
    Treatment outcomes of multidrug-resistant TB with selective use of new drugs.
    Int J Tuberc Lung Dis. 2023;27:55-60.
    >> Share

  173. ZENG C, Mitnick CD, Hewison C, Bastard M, et al
    Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:34-40.
    >> Share

  174. CANTERA JL, Rashid AA, Lillis LM, Peck RB, et al
    Isolation and purification of lipoarabinomannan from urine of adults with active TB.
    Int J Tuberc Lung Dis. 2023;27:75-77.
    >> Share

  175. KNUDSEN S, Babu SP, Ramakrishnan J, Jenkins HE, et al
    M. tuberculosis infection before, during and after pregnancy.
    Int J Tuberc Lung Dis. 2023;27:72-74.
    >> Share

  176. ATSHEMYAN H, Khachatryan N, Manukyan A, Khachatryan A, et al
    Implementation of modified, all-oral shorter TB regimens in Armenia.
    Int J Tuberc Lung Dis. 2023;27:84-85.
    >> Share

  177. BUTOV D, Feshchenko Y, Chesov D, Myasoedov V, et al
    National survey on the impact of the war in Ukraine on TB diagnostics and treatment services in 2022.
    Int J Tuberc Lung Dis. 2023;27:86-88.
    >> Share

  178. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
    Sugar and sugar-free liquid formulations of delamanid for patients with rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2023;27:13-18.
    >> Share

  179. MAH JK, Lieu A, Fisher D, Lim RK, et al
    Impact of the COVID-19 pandemic on the epidemiology of TB in a low-incidence setting.
    Int J Tuberc Lung Dis. 2023;27:69-71.
    >> Share

  180. COX SR, Padmapriyadarsini C, Mave V, Seth B, et al
    Characterising cause of death among people treated for drug-susceptible TB in India.
    Int J Tuberc Lung Dis. 2023;27:78-80.
    >> Share

  181. JAW-TSAI S, Barry R, Pande PG, Taneja R, et al
    Comparison of pharmacokinetics and bioavailability of bedaquiline fumarate, benzoate and maleate in dogs.
    Int J Tuberc Lung Dis. 2023;27:28-33.
    >> Share

  182. DE HAAS P, Nhung NV, Hng NT, Hoa NB, et al
    Introduction of the Simple One-Step stool Xpert Ultra method to detect TB in children and adults.
    Int J Tuberc Lung Dis. 2023;27:19-27.
    >> Share

    December 2022
  183. NOESKE J, Kuaban C
    Tailored TB preventive treatment for drug-resistant TB - failing the test for appropriateness?
    Int J Tuberc Lung Dis. 2022;26:1198.
    >> Share

  184. ALFFENAAR JWC, Marais BJ, Touw DJ
    Paediatric formulations for the treatment of drug resistant TB: closing the gaps.
    Int J Tuberc Lung Dis. 2022;26:1097-1100.
    >> Share

  185. IZUDI J, Sheira LA, Bajunirwe F, McCoy SI, et al
    Effect of 6-month vs. 8-month regimen on retreatment success for pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:1188-1190.
    >> Share

  186. DATTA A, Mohapatra PR, Bhuniya S, Mishra B, et al
    TB treatment regimen for children: is a 4-month regimen really better than the 6-month regimen?
    Int J Tuberc Lung Dis. 2022;26:1197.
    >> Share

  187. TANEJA R, Nahata MC, Scarim J, Pande PG, et al
    Stable sugar and sugar-free suspensions of pretomanid.
    Int J Tuberc Lung Dis. 2022;26:1112-1117.
    >> Share

  188. DEVOID I, Sillah AK, Sutherland J, Owolabi O, et al
    The household economic burden of drug-susceptible TB diagnosis and treatment in The Gambia.
    Int J Tuberc Lung Dis. 2022;26:1162-1169.
    >> Share

  189. MEMANI B, Furin J, Cox H, Reuter A, et al
    A very sneaky bug: perspectives of front-line clinicians on whole-genome sequencing for drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:1180-1182.
    >> Share

  190. CARTER EJ, Mungai B, Njoroge T, Masese A, et al
    Finding the missing children for TB care and prevention in Kenya.
    Int J Tuberc Lung Dis. 2022;26:1144-1150.
    >> Share

    November 2022
  191. GRANOZZI B, Bisognin F, Tadolini M, Lombardi G, et al
    IGRA test for TB in COVID-19: role of corticosteroids.
    Int J Tuberc Lung Dis. 2022;26:1088-1091.
    >> Share

  192. SMITH-JEFFCOAT SE, Eisenach KD, Joloba M, Ssengooba W, et al
    Quantification of multidrug-resistant M. tuberculosis bacilli in sputum during the first 8 weeks of treatment.
    Int J Tuberc Lung Dis. 2022;26:1058-1064.
    >> Share

  193. GARCIA-GOEZ JF, Tello-Cajiao ME, Vargas-Potes CJ, Penagos-Luna R, et al
    Effect of biological therapies on TB treatment outcomes.
    Int J Tuberc Lung Dis. 2022;26:1077-1079.
    >> Share

  194. DIEFENBACH-ELSTOB T, Rivest P, Benedetti A, Gordon C, et al
    Patterns and characteristics of TB among key risk groups in Canada, 1993-2018.
    Int J Tuberc Lung Dis. 2022;26:1041-1049.
    >> Share

  195. VELAYUTHAM B, Shah V, Mythily V, Gopalaswamy R, et al
    Factors influencing treatment outcomes in patients with isoniazid-resistant pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:1033-1040.
    >> Share

  196. WILLEMSTEIN IJM, de Vries G, Essink DR, Slump E, et al
    TB in migrants residing in the Netherlands for at least 5 years at diagnosis, 2003-2018.
    Int J Tuberc Lung Dis. 2022;26:1050-1057.
    >> Share

  197. KRISHNAN N, Siddiqi K, Dogar O, Gabe R, et al
    Predictors of long-term smoking abstinence in TB patients.
    Int J Tuberc Lung Dis. 2022;26:1074-1076.
    >> Share

  198. BARRETT R, Creswell J, Sahu S, Qin ZZ, et al
    User perspectives on the use of X-rays and computer-aided detection for TB.
    Int J Tuberc Lung Dis. 2022;26:1083-1085.
    >> Share

  199. TRAORE M, Nguhiu P, Telly N, Traore S, et al
    The high costs facing TB-affected households in Mali.
    Int J Tuberc Lung Dis. 2022;26:1071-1073.
    >> Share

    October 2022
  200. AIA P, Viney K, Kal M, Kisomb J, et al
    The economic burden of TB faced by patients and affected families in Papua New Guinea.
    Int J Tuberc Lung Dis. 2022;26:934-941.
    >> Share

  201. MARAIS BJ, Bernays S, Schaaf HS, Fox GJ, et al
    Increasing TB preventive treatment in children.
    Int J Tuberc Lung Dis. 2022;26:903-905.
    >> Share

  202. TYEKU N, Apolisi I, Daniels J, Beko B, et al
    Pediatric delamanid treatment for children with rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:986-988.
    >> Share

  203. MENEZES D, Zenner D, Aldridge R, Anderson SR, et al
    Country differences and determinants of yield in programmatic migrant TB screening in four European countries.
    Int J Tuberc Lung Dis. 2022;26:942-948.
    >> Share

  204. CATES L, Codreanu A, Ciobanu N, Fosburgh H, et al
    Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova.
    Int J Tuberc Lung Dis. 2022;26:963-969.
    >> Share

  205. BLACKBOURN H, Tiberi S, Felker I
    Literature Highlights.
    Int J Tuberc Lung Dis. 2022;26:914-916.
    >> Share

  206. PORRETTA AD, Manga S, Pontali E
    TB care in prisons: the ongoing challenge.
    Int J Tuberc Lung Dis. 2022;26:906-907.
    >> Share

  207. DIALLO A, Combary A, Bakyono R, Guene H, et al
    A 2020 baseline assessment for the monitoring of the End TB indicator of catastrophic costs in Burkina Faso.
    Int J Tuberc Lung Dis. 2022;26:970-977.
    >> Share

  208. ROUZIER V, Murrill M, Kim S, Naini L, et al
    Caregiver willingness to give TPT to children living with drug-resistant TB patients.
    Int J Tuberc Lung Dis. 2022;26:949-955.
    >> Share

  209. SCHWALB A, Emery JC, Houben RMGJ
    Use of chest radiography screening for TB: a re-evaluation of the Kolin study.
    Int J Tuberc Lung Dis. 2022;26:983-985.
    >> Share

  210. FATIMA R, Yaqoob A, Qadeer E, Khan MA, et al
    Community- vs. hospital-based management of multidrug-resistant TB in Pakistan.
    Int J Tuberc Lung Dis. 2022;26:929-933.
    >> Share

  211. MANGOCHI P, Bossard C, Catacutan C, Van Laeken D, et al
    TB screening, prevention and treatment cascade in a Malawi prison.
    Int J Tuberc Lung Dis. 2022;26:956-962.
    >> Share

    September 2022
  212. FARIA N, Reis R
    Screening for TB infection: the operator s impact.
    Int J Tuberc Lung Dis. 2022;26:857-861.
    >> Share

  213. MOHAPATRA PR, Mishra B, Dutta A, Bhuniya S, et al
    Responding to WHO s 4-month regimen for drug-susceptible pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:898-899.
    >> Share

  214. KHAN U, Guglielmetti L
    Evidence and ethical considerations for the treatment of contacts exposed to drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:900-901.
    >> Share

  215. SABI I, Olomi W, Nkereuwem E, Togun T, et al
    Diagnosis of paediatric TB using Xpert((R)) MTB/RIF Ultra on fresh respiratory samples.
    Int J Tuberc Lung Dis. 2022;26:862-868.
    >> Share

  216. SANTOS AP, Silva DR, Miranda G, Braga MS, et al
    Xpert((R)) MTB/RIF Ultra: detection of extrapulmonary TB in a high-burden setting.
    Int J Tuberc Lung Dis. 2022;26:880-882.
    >> Share

  217. DURET A, Olgemoeller F, Ferreras-Antolin L, Whittaker E, et al
    Paediatric TB care in the United Kingdom.
    Int J Tuberc Lung Dis. 2022;26:814-819.
    >> Share

  218. SHUKLA A, Bromage S, Dholakia Y, Hemler EC, et al
    Case-control study of vitamin D status and adult multidrug-resistant pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:826-834.
    >> Share

  219. CHO EJ, Kang MR, Kim JH, Lee JI, et al
    Evaluation of the MolecuTech((R)) REBA MTB-XMDR kit for detection of pre-extensively drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:869-874.
    >> Share

  220. SCHWALB A, Cachay R, Wright A, Phillips PPJ, et al
    Factors associated with screening failure and study withdrawal in multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:820-825.
    >> Share

  221. TABERNERO E, Rodrigo T, Garros J, Altube L, et al
    TB in the elderly: clinical features and outcomes.
    Int J Tuberc Lung Dis. 2022;26:842-849.
    >> Share

  222. KRAEF C, Yedilbayev A, Seguy N, Bentzon A, et al
    Uptake of the lateral flow urine LAM test in Europe and Central Asia.
    Int J Tuberc Lung Dis. 2022;26:835-841.
    >> Share

    August 2022
  223. WEBER SF, Ruby LC, Heller T, Hande M, et al
    TB disease patterns by HIV and diabetes status.
    Int J Tuberc Lung Dis. 2022;26:733-740.
    >> Share

  224. MALIK AA, Siddique M, Chandir S, Jaswal M, et al
    Travel reimbursements, distance to health facility and preventive treatment cascade for drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:789-791.
    >> Share

  225. MAGOHE A, Kimario J, Lukmanji Z, Hendricks K, et al
    Randomized, controlled trial of a protein-calorie supplement for women coinfected with HIV-TB.
    Int J Tuberc Lung Dis. 2022;26:798-800.
    >> Share

  226. JASWAL M, Farooq S, Madhani F, Noorani S, et al
    Implementing 3HP vs. IPT as TB preventive treatment in Pakistan.
    Int J Tuberc Lung Dis. 2022;26:741-746.
    >> Share

  227. CASALME DJO, Marcelo DB, Dela Cuesta DM, Tonquin M, et al
    Feasibility and acceptability of asynchronous VOT among patients with MDR-TB.
    Int J Tuberc Lung Dis. 2022;26:760-765.
    >> Share

  228. CHHABRA S, Ong CWM, Sotgiu G
    TB diagnosis and treatment during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2022;26:702-703.
    >> Share

  229. VERGEER SB, Oldenkamp R, Senkoro M, Mfinanga S, et al
    Does distance to healthcare facility affect care-seeking for TB-related symptoms in Tanzania?
    Int J Tuberc Lung Dis. 2022;26:747-752.
    >> Share

  230. GEBRESELASSIE N, Falzon D, Zignol M, Viney K, et al
    Bridging the gap: key evidence needed to strengthen global policies to end TB.
    Int J Tuberc Lung Dis. 2022;26:704-707.
    >> Share

  231. NAQVI S, Cantu Y, Ong Uti S, Cavazos D, et al
    Successes and challenges of latent TB screening and treatment in a high-prevalence US region.
    Int J Tuberc Lung Dis. 2022;26:720-726.
    >> Share

  232. KOKEBU DM, Ahmed S, Moodliar R, Chiang CY, et al
    Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB.
    Int J Tuberc Lung Dis. 2022;26:753-759.
    >> Share

  233. GIANNONI F, Lanni A, Iacobino A, Cirillo DM, et al
    Decreasing trend of drug-resistant TB in Italy.
    Int J Tuberc Lung Dis. 2022;26:775-783.
    >> Share

  234. REKART ML, Morshed T, Mulanda WK, Klieascikova J, et al
    Family directly observed therapy for children with drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:792-794.
    >> Share

    July 2022
  235. ISMAIL F, Yousif A, Alfurjani M, Haq S, et al
    TB in eastern Libya: a decreasing trend in recent decades.
    Int J Tuberc Lung Dis. 2022;26:694-695.
    >> Share

  236. BASHAM CA, Orr PH
    Monitoring TB program performance.
    Int J Tuberc Lung Dis. 2022;26:692-693.
    >> Share

  237. NAIR P, Hasan T, Zaw KK, Allamuratova S, et al
    Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Int J Tuberc Lung Dis. 2022;26:658-663.
    >> Share

  238. CARVALHO ACC, Kritski AL
    Community-based intervention and health education to scale up TB preventive treatment for children.
    Int J Tuberc Lung Dis. 2022;26:587-589.
    >> Share

  239. AKKERMAN OW, Duarte R, Tiberi S, Schaaf HS, et al
    Clinical standards for drug-susceptible pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:592-604.
    >> Share

  240. VAN DER WERF TS, Grobusch MP
    Clinical standards for drug-susceptible TB: putting patients first.
    Int J Tuberc Lung Dis. 2022;26:584-586.
    >> Share

  241. NGUENHA D, Acacio S, Murias-Closas A, Ramanlal N, et al
    Prevalence and clinical characteristics of pulmonary TB among pregnant and post-partum women.
    Int J Tuberc Lung Dis. 2022;26:641-649.
    >> Share

  242. VARSHNEY K, Rusnak JC
    TB reporting declines in priority countries during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2022;26:681-683.
    >> Share

  243. WEYENGA H, Onyango E, Katana AK, Pathmanathan I, et al
    Trends in TB and HIV care and treatment cascade, Kenya, 2008-2018.
    Int J Tuberc Lung Dis. 2022;26:623-628.
    >> Share

  244. MIGLIORI GB, Tiberi S
    WHO drug-resistant TB guidelines 2022: what is new?
    Int J Tuberc Lung Dis. 2022;26:590-591.
    >> Share

  245. KAMBILI C, Rossenu S, Hoetelmans RMW, Birmingham E, et al
    Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:671-677.
    >> Share

    June 2022
  246. LAZARCHIK A, Nyaruhirira AU, Chiang CY, Wares F, et al
    Global availability of susceptibility testing for second-line anti-tuberculosis agents.
    Int J Tuberc Lung Dis. 2022;26:524-528.
    >> Share

  247. PELZER PT, Smit Y, Tiemersma EW, Huong NT, et al
    Does BCG vaccination protect against infection with M. tuberculosis?
    Int J Tuberc Lung Dis. 2022;26:529-536.
    >> Share

  248. SINHA P, Bhargava A, Carwile M, Cintron C, et al
    Undernutrition can no longer be an afterthought for global efforts to eliminate TB.
    Int J Tuberc Lung Dis. 2022;26:477-480.
    >> Share

  249. BOEKELHEIDE K, Olugbosi M, Nedelman J, Everitt D, et al
    Male reproductive hormones in patients treated with pretomanid.
    Int J Tuberc Lung Dis. 2022;26:558-565.
    >> Share

  250. KANIGA K, Lounis N, Zhuo S, Bakare N, et al
    Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline.
    Int J Tuberc Lung Dis. 2022;26:571-573.
    >> Share

  251. LAURSEN LL, Dahl VN, Wejse C
    Stool testing for pulmonary TB diagnosis in adults.
    Int J Tuberc Lung Dis. 2022;26:516-523.
    >> Share

  252. SHIN AY, Jekarl DW, Kim HW, Ha JH, et al
    Early line-probe assay using DNA specimens in patients with pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:509-515.
    >> Share

  253. NAUFAL F, Chaisson LH, Robsky KO, Delgado-Barroso P, et al
    Number needed to screen for TB in clinical, structural or occupational risk groups.
    Int J Tuberc Lung Dis. 2022;26:500-508.
    >> Share

  254. MALIK AA, Amanullah F
    Source case investigation can reduce the diagnostic gap for childhood TB.
    Int J Tuberc Lung Dis. 2022;26:566-567.
    >> Share

    May 2022
  255. GRANOZZI B, Bisognin F, Lombardi G, Dal Monte P, et al
    TB mortality in low-incidence countries: can we reduce it further?
    Int J Tuberc Lung Dis. 2022;26:467-469.
    >> Share

  256. GROSCHEL MI, van den Boom M, Dixit A, Skrahina A, et al
    Management of childhood MDR-TB in Europe and Central Asia: report of a Regional WHO meeting.
    Int J Tuberc Lung Dis. 2022;26:433-440.
    >> Share

  257. SHAMPUTA IC, Nguyen DTK, Burdo T, Dao G, et al
    Canadian immigrants awareness and perceptions of TB infection and TB.
    Int J Tuberc Lung Dis. 2022;26:454-456.
    >> Share

  258. COOREY NJ, Kensitt L, Davies J, Keller E, et al
    Risk factors for TB in Australia and their association with delayed treatment completion.
    Int J Tuberc Lung Dis. 2022;26:399-405.
    >> Share

  259. KRITSKI AL, Viveiros M, Carvalho ACC
    Rapid molecular diagnostics to detect resistance to second-line anti-TB drugs.
    Int J Tuberc Lung Dis. 2022;26:385-387.
    >> Share

  260. GANDHI R, Deepak KG, Verma G, Chaubey S, et al
    Engaging private pharmacies to help end TB in India.
    Int J Tuberc Lung Dis. 2022;26:457-459.
    >> Share

  261. NINAN MM, Rupali P, Varghese GM, Shalini EB, et al
    Xpert Ultra in diagnosing extrapulmonary TB: accuracy and trace calls.
    Int J Tuberc Lung Dis. 2022;26:441-445.
    >> Share

  262. MALIK AA, Hussain H
    Preventive treatment for MDR-TB exposure in households.
    Int J Tuberc Lung Dis. 2022;26:466-467.
    >> Share

  263. CAPEDING TPJ, Rosa JD, Lam H, Gaviola DG, et al
    Cost of TB prevention and treatment in the Philippines in 2017.
    Int J Tuberc Lung Dis. 2022;26:392-398.
    >> Share

  264. PALANI N, Premkumar M, Vaishnavee V, Dinesh V, et al
    Trends in rifampicin and isoniazid resistance in patients with presumptive TB.
    Int J Tuberc Lung Dis. 2022;26:446-453.
    >> Share

    April 2022
  265. MARCHESE V, Formenti B, Marchese L, Gregori N, et al
    COVID-19 effect on TB presentation and outcome.
    Int J Tuberc Lung Dis. 2022;26:375-377.
    >> Share

  266. KIM JW, Vella C, Parvez W, Verma R, et al
    Impact of COVID-19 on the diagnosis and management of lung cancer and TB.
    Int J Tuberc Lung Dis. 2022;26:372-374.
    >> Share

  267. ALLORANT A, Biswas S, Ahmed S, Wiens KE, et al
    Finding gaps in routine TB surveillance activities in Bangladesh.
    Int J Tuberc Lung Dis. 2022;26:356-362.
    >> Share

  268. SHIVAKUMAR SVBY, Padmapriyadarsini C, Chavan A, Paradkar M, et al
    Concomitant pulmonary disease is common among patients with extrapulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:341-347.
    >> Share

  269. HUGHES G, Bern H, Chiang CY, Goodall RL, et al
    QT prolongation in the STREAM Stage 1 Trial.
    Int J Tuberc Lung Dis. 2022;26:334-340.
    >> Share

  270. DEN BOON S, Lienhardt C, Zignol M, Schwartzman K, et al
    WHO target product profiles for TB preventive treatment.
    Int J Tuberc Lung Dis. 2022;26:302-309.
    >> Share

  271. ADAMASHVILI N, Baliashvili D, Kuchukhidze G, Salindri AD, et al
    Low BMI increases all-cause mortality rates in patients with drug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:326-333.
    >> Share

  272. PRADHAN NN, Paradkar MS, Kagal A, Valvi C, et al
    Performance of Xpert((R)) MTB/RIF and Xpert((R)) Ultra for the diagnosis of tuberculous meningitis in children.
    Int J Tuberc Lung Dis. 2022;26:317-325.
    >> Share

  273. DOWDY DW, Islam MA
    Finding TB s "missing millions", one district at a time.
    Int J Tuberc Lung Dis. 2022;26:295.
    >> Share

    March 2022
  274. SUMNER T, Jensen HT, Keogh-Brown MR, Vassall A, et al
    Time to integrate epidemiological and economic models for TB.
    Int J Tuberc Lung Dis. 2022;26:282-284.
    >> Share

  275. MBELELE PM, Sabiiti W, Heysell SK, Sauli E, et al
    Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease.
    Int J Tuberc Lung Dis. 2022;26:276-278.
    >> Share

  276. MUSONDA HK, Rose PC, Switala J, Schaaf HS, et al
    Paediatric admissions to a TB hospital: reasons for admission, clinical profile and outcomes.
    Int J Tuberc Lung Dis. 2022;26:217-223.
    >> Share

  277. MIGLIORI GB, Wu SJ, Matteelli A, Zenner D, et al
    Clinical standards for the diagnosis, treatment and prevention of TB infection.
    Int J Tuberc Lung Dis. 2022;26:190-205.
    >> Share

    February 2022
  278. TINOCO EM, Vasconcelos A, Alves F, Duarte R, et al
    Impact of COVID-19 on extrapulmonary TB and the benefit of decentralised TB services.
    Int J Tuberc Lung Dis. 2022;26:178-180.
    >> Share

  279. ORTIZ-MARTINEZ Y, Rodriguez-Morales AJ, Henao-Martinez AF
    Decreased notification of TB cases during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2022;26:177-178.
    >> Share

  280. SCHIZA V, Kruse M, Xiao Y, Kar S, et al
    Impact of the COVID-19 pandemic on TB infection testing.
    Int J Tuberc Lung Dis. 2022;26:174-176.
    >> Share

  281. GUREVA T, Turkova A, Yablokova E, Smirnova P, et al
    Fluoroquinolone preventive therapy for children exposed to MDR-TB.
    Int J Tuberc Lung Dis. 2022;26:171-173.
    >> Share

  282. BOHLBRO AS, Patsche CB, Mendes AM, Sifna A, et al
    A self-rated health score predicts severe disease and high mortality in patients with pulmonary TB.
    Int J Tuberc Lung Dis. 2022;26:158-165.
    >> Share

  283. MOHR-HOLLAND E, Daniels J, Reuter A, Rodriguez CA, et al
    Early mortality during rifampicin-resistant TB treatment.
    Int J Tuberc Lung Dis. 2022;26:150-157.
    >> Share

  284. BEAUMONT AL, Doumbia A, Chateau N, Meynard JL, et al
    Why are people still dying of drug-susceptible TB in Paris in the 21(st) century?
    Int J Tuberc Lung Dis. 2022;26:142-149.
    >> Share

  285. LOPEZ-VARELA E, Garcia-Prats AJ, Seddon JA, Draper HR, et al
    Treatment outcomes and safety in children with rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:133-141.
    >> Share

  286. BURHAN E, Soepandi PZ, Isbaniah F, Damayanti K, et al
    Determinants of treatment outcomes in patients with multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2022;26:126-132.
    >> Share

  287. HOSSAIN MD, Rahim MA, Islam N, Afroze F, et al
    TB prevalence among patients with diabetes in Bangladesh.
    Int J Tuberc Lung Dis. 2022;26:119-125.
    >> Share

  288. KHAWCHAROENPORN T, Noisang K
    Incomplete contact investigation and risk of developing TB among healthcare professionals.
    Int J Tuberc Lung Dis. 2022;26:111-118.
    >> Share

  289. APRIANI L, Koesoemadinata RC, Bastos ML, Wulandari DA, et al
    Implementing the 4R and 9H regimens for TB preventive treatment in Indonesia.
    Int J Tuberc Lung Dis. 2022;26:103-110.
    >> Share

  290. ILAIWY G, Heysell SK, Thomas TA
    National approaches to TB care in adolescents.
    Int J Tuberc Lung Dis. 2022;26:96-102.
    >> Share

  291. SILVA DR, de Queiroz Mello FC
    Improving outcomes for multidrug-resistant TB treatment.
    Int J Tuberc Lung Dis. 2022;26:93-95.
    >> Share

  292. BARRETT J
    Why are people still dying from TB in low-burden countries?
    Int J Tuberc Lung Dis. 2022;26:91-92.
    >> Share

  293. HARRIES AD, Zellweger JP
    Protecting healthcare workers from TB.
    Int J Tuberc Lung Dis. 2022;26:89-90.
    >> Share

  294. GRAHAM SM, Amanullah F
    Updated guidelines for child and adolescent TB.
    Int J Tuberc Lung Dis. 2022;26:81-84.
    >> Share

  295. LANGE C, Kay A, Mandalakas AM
    The need for effective drugs for TB prevention: set your goals high, and don t stop till you get there.
    Int J Tuberc Lung Dis. 2022;26:85-88.
    >> Share

    January 2022
  296. TADOLINI M, Onozaki I
    National TB prevalence surveys in the COVID-19 era.
    Int J Tuberc Lung Dis. 2022;26:4-5.
    >> Share

  297. SINHA P, White LF, Hochberg NS, Cegielski JP, et al
    Avoiding pitfalls in calculating the population attributable fraction of undernutrition for TB.
    Int J Tuberc Lung Dis. 2022;26:80.
    >> Share

  298. KLAOS K, Holicka Y, Groenheit R, Kodmon C, et al
    Current state of national TB laboratory networks in Europe: achievements and challenges.
    Int J Tuberc Lung Dis. 2022;26:71-73.
    >> Share

  299. OJUAWO O, Piracha S, Irshad S, Mirza M, et al
    Tuberculous mastitis in a low-incidence setting: should respiratory physicians be concerned?
    Int J Tuberc Lung Dis. 2022;26:69-70.
    >> Share

  300. PETRUCCIOLI E, Farroni C, Cuzzi G, Vanini V, et al
    VIDAS((R)) TB-IGRA reagents induce a CD4(+) and CD8(+) T-cell IFN-gamma response for both TB infection and active TB.
    Int J Tuberc Lung Dis. 2022;26:65-68.
    >> Share

  301. CHIPINDURO M, Timire C, Chirenda J, Matambo R, et al
    TB prevalence in Zimbabwe: a national cross-sectional survey, 2014.
    Int J Tuberc Lung Dis. 2022;26:57-64.
    >> Share

  302. ACOSTA J, Flores P, Alarcon M, Grande-Ortiz M, et al
    A randomised controlled trial to evaluate a medication monitoring system for TB treatment.
    Int J Tuberc Lung Dis. 2022;26:44-49.
    >> Share

    December 2021
  303. ZAMANI S, Honarvar MR, Behnampour N, Sheikhy M, et al
    Decline in TB incidence during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2021;25:1043-1044.
    >> Share

  304. SUMNER T, Fiore-Gartland A, Hatherill M, Houben RMGJ, et al
    The effect of new Mycobacterium tuberculosis infection on the sensitivity of prognostic TB signatures.
    Int J Tuberc Lung Dis. 2021;25:1001-1005.
    >> Share

  305. SARDA R, Ray A
    Pulmonary TB and chronic pulmonary aspergillosis.
    Int J Tuberc Lung Dis. 2021;25:1042-1043.
    >> Share

  306. TESFAHUN H, Moussally K, Al-Ani NA, Al-Salhi LG, et al
    Introduction of new drugs for drug-resistant TB in Iraq.
    Int J Tuberc Lung Dis. 2021;25:1041-1042.
    >> Share

  307. CHATTERJEE S, Toshniwal MN, Bhide P, Sachdeva KS, et al
    Costs of TB services in India (No 1).
    Int J Tuberc Lung Dis. 2021;25:1013-1018.
    >> Share

  308. ZHU H, Xie L, Liu ZQ, Wang B, et al
    Population pharmacokinetics of bedaquiline in patients with drug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:1006-1012.
    >> Share

  309. NIKOLENKA A, Mansjo M, Skrahina A, Hurevich H, et al
    Whole-genome sequencing differentiates relapse from re-infection in TB.
    Int J Tuberc Lung Dis. 2021;25:995-1000.
    >> Share

  310. LEE JJ, Kang HY, Lee WI, Cho SY, et al
    Efflux pump gene expression study using RNA-seq in multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:974-981.
    >> Share

  311. TELISINGHE L, Shaweno D, Hayes RJ, Dodd PJ, et al
    The effect of systematic screening of the general population on TB case notification rates.
    Int J Tuberc Lung Dis. 2021;25:964-973.
    >> Share

    November 2021
  312. ANTONY S, Bodhanwala M, Shah I
    Clinical profile and outcomes of paediatric central nervous system tuberculomas.
    Int J Tuberc Lung Dis. 2021;25:953-955.
    >> Share

  313. FUKUSHIMA K, Akagi K, Kondoh A, Kubo T, et al
    Evaluation of QFT-Plus performance using blood samples stored at room temperature.
    Int J Tuberc Lung Dis. 2021;25:948-949.
    >> Share

  314. WOLTERS BA, Aartsma Y, Jansen K, van Hest R, et al
    Travel history and challenges of screening for latent TB infection in child asylum seekers.
    Int J Tuberc Lung Dis. 2021;25:945-947.
    >> Share

  315. CHRISTOPHER DJ, Coelho V, Ebby GS, Shankar D, et al
    Incremental yield of Xpert((R)) MTB/RIF Ultra over Xpert((R)) MTB/RIF in the diagnosis of extrapulmonary TB.
    Int J Tuberc Lung Dis. 2021;25:939-944.
    >> Share

  316. GATECHOMPOL S, Sophonphan J, Kerr SJ, Ubolyam S, et al
    Monocyte-to-lymphocyte ratio as a predictor of TB among people living with HIV.
    Int J Tuberc Lung Dis. 2021;25:933-938.
    >> Share

  317. KASWA M, Minga G, Nkiere N, Mingiedi B, et al
    The economic burden of TB-affected households in DR Congo.
    Int J Tuberc Lung Dis. 2021;25:923-932.
    >> Share

  318. STIEBER F, Howard J, Manissero D, Boyle J, et al
    Evaluation of a lateral-flow nanoparticle fluorescence assay for TB infection diagnosis.
    Int J Tuberc Lung Dis. 2021;25:917-922.
    >> Share

  319. MURITHI W, Click ES, McCarthy KD, Okeyo E, et al
    Need for caution when interpreting Xpert((R)) MTB/RIF results for rifampin resistance among children.
    Int J Tuberc Lung Dis. 2021;25:911-916.
    >> Share

  320. LUAN L, Fraisse P, Cordel H, Charlois C, et al
    Screening for active and latent TB among migrants in France.
    Int J Tuberc Lung Dis. 2021;25:903-910.
    >> Share

  321. WINCKLER JL, Schaaf HS, Draper HR, McIlleron H, et al
    Pharmacokinetics of high-dose isoniazid in children affected by multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:896-902.
    >> Share

  322. TAAFFE J, Croda J, Moultrie H, Silva DS, et al
    Advancing TB research using digitized programmatic data.
    Int J Tuberc Lung Dis. 2021;25:890-895.
    >> Share

  323. BOEREE MJ, Lange C, Thwaites G, Paton N, et al
    UNITE4TB: a new consortium for clinical drug and regimen development for TB.
    Int J Tuberc Lung Dis. 2021;25:886-889.
    >> Share

  324. OCHERETINA O, Brandao AP, Pang Y, Rodrigues C, et al
    Impact of the bacillary load on the accuracy of rifampicin resistance results by Xpert((R)) MTB/RIF.
    Int J Tuberc Lung Dis. 2021;25:881-885.
    >> Share

  325. ALFFENAAR JC, Marais BJ, Thomas TA
    Is a high dose sufficient to achieve high isoniazid exposure in children affected by multidrug-resistant TB?
    Int J Tuberc Lung Dis. 2021;25:879-880.
    >> Share

    October 2021
  326. SEKANDI JN, Tucker EG, Zalwango S, Buregyeya E, et al
    Digital technologies and loss to follow-up for TB patients.
    Int J Tuberc Lung Dis. 2021;25:871-872.
    >> Share

  327. HASSAN L, Ali SM, Iqbal W, Baig S, et al
    Automated detection and reduction of stigma in online discussions about TB.
    Int J Tuberc Lung Dis. 2021;25:869-870.
    >> Share

  328. ARENAS-MIRAS M, Sanchez-Martinez F, Jove-Caballe N, Villar-Garcia J, et al
    Clinical experience of TB in patients treated with anti-TNF-alpha.
    Int J Tuberc Lung Dis. 2021;25:866-868.
    >> Share

  329. TAHSEEN S, Khanzada FM, Hussain A, Akhtar N, et al
    Phenotypic vs. genotypic resistance to fluoroquinolones in rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:861-863.
    >> Share

  330. EJO M, Van Deun A, Nunn A, Meredith S, et al
    Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial.
    Int J Tuberc Lung Dis. 2021;25:839-845.
    >> Share

  331. BLACK M, Da Silva P, Scott L
    Rifampicin-resistant TB: discordance between Xpert((R)) MTB/RIF and MTBDRplus results.
    Int J Tuberc Lung Dis. 2021;25:832-838.
    >> Share

  332. OXLADE O, den Boon S, Menzies D, Falzon D, et al
    TB preventive treatment in high- and intermediate-incidence countries: research needs for scale-up.
    Int J Tuberc Lung Dis. 2021;25:823-831.
    >> Share

  333. PURCHASE S, Batist E, Mmile N, Nkosi S, et al
    Challenges in recruiting children to a multidrug-resistant TB prevention trial.
    Int J Tuberc Lung Dis. 2021;25:814-822.
    >> Share

    September 2021
  334. KOZINSKA M, Podlasin R, Ropelewska-Lacka K, Wojtycha-Kwasnica B, et al
    TB and COVID-19 coinfection.
    Int J Tuberc Lung Dis. 2021;25:776-777.
    >> Share

  335. MOHR-HOLLAND E, Hacking D, Daniels J, Scott V, et al
    Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19.
    Int J Tuberc Lung Dis. 2021;25:772-775.
    >> Share

  336. GIGANTE AR, Sousa M, Aguiar A, Pinto M, et al
    The impact of COVID-19 on the TB response: data from the field.
    Int J Tuberc Lung Dis. 2021;25:769-771.
    >> Share

  337. SHIN JE, Jo KW, O YJ, Jeon D, et al
    Impact of revised definitions for extensively drug-resistant TB on disease classification.
    Int J Tuberc Lung Dis. 2021;25:766-768.
    >> Share

  338. GUTIERREZ A, Isidro A, Herrerin J, Hinojosa J, et al
    Meningeal TB in a mummified child from 4,000 years ago.
    Int J Tuberc Lung Dis. 2021;25:761-762.
    >> Share

  339. KAMOLWAT P, Nonghanphithak D, Chaiprasert A, Smithtikarn S, et al
    Diagnostic performance of whole-genome sequencing for identifying drug-resistant TB in Thailand.
    Int J Tuberc Lung Dis. 2021;25:754-760.
    >> Share

  340. HUDDART S, Ingawale P, Edwin J, Jondhale V, et al
    TB case fatality and recurrence in a private sector cohort in Mumbai, India.
    Int J Tuberc Lung Dis. 2021;25:738-746.
    >> Share

  341. MOODLIAR R, Aksenova V, Frias MVG, van de Logt J, et al
    Bedaquiline for multidrug-resistant TB in paediatric patients.
    Int J Tuberc Lung Dis. 2021;25:716-724.
    >> Share

  342. MURPHY RA, Douglas-Jones B, Mucinya G, Sunpath H, et al
    Expanding the use of dolutegravir-based antiretroviral therapy in multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:696-700.
    >> Share

  343. CHESOV D, Makhanda G, Furin J
    Tackling the many layers of stigma is essential for the "End TB Strategy".
    Int J Tuberc Lung Dis. 2021;25:683-684.
    >> Share

    August 2021
  344. RANAIVOMANANA P, Knoblauch AM, Razafimahatratra MC, Raherinandrasana AH, et al
    Pulmonary and pleural TB prevalence in pregnant women.
    Int J Tuberc Lung Dis. 2021;25:668-670.
    >> Share

  345. EDDY JJ, Seth B, White LF, Sulis CA, et al
    Decreasing time spent in airborne infection isolation during TB testing.
    Int J Tuberc Lung Dis. 2021;25:665-667.
    >> Share

  346. CLARKSON MC, McQuaid CF, Houben RM, Kranzer K, et al
    Better data for country-level TB resource allocation are urgently required.
    Int J Tuberc Lung Dis. 2021;25:662-664.
    >> Share

  347. PERRY A, Chitnis A, Chin A, Hoffmann C, et al
    Real-world implementation of video-observed therapy in an urban TB program in the United States.
    Int J Tuberc Lung Dis. 2021;25:655-661.
    >> Share

  348. SMITH AGC, Gujabidze M, Avaliani T, Blumberg HM, et al
    Clinical outcomes among patients with tuberculous meningitis receiving intensified treatment regimens.
    Int J Tuberc Lung Dis. 2021;25:632-639.
    >> Share

  349. SHARMA K, Sharma M, Modi M, Singla N, et al
    Comparative analysis of Truenat MTB Plus and Xpert((R)) Ultra in diagnosing tuberculous meningitis.
    Int J Tuberc Lung Dis. 2021;25:626-631.
    >> Share

  350. CAMPBELL JR, Katamba A, Oxlade O, Schwartzman K, et al
    Improving country-level modelling to support TB prevention and care.
    Int J Tuberc Lung Dis. 2021;25:607-608.
    >> Share

  351. DONOVAN J, Walker TM
    Diagnosing tuberculous meningitis: a testing process.
    Int J Tuberc Lung Dis. 2021;25:605-606.
    >> Share

    July 2021
  352. AMOUR M, von Reyn CF
    A new paradigm: testing household contacts of adolescents with incident TB infection.
    Int J Tuberc Lung Dis. 2021;25:599b-600.
    >> Share

  353. RODRIGUEZ CA, Brooks MB, Aibana O, Mitnick CD, et al
    Sputum culture conversion definitions and analytic practices for multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:596-598.
    >> Share

  354. ERISA KC, Robsky KO, Kitonsa PJ, Nalutaaya A, et al
    Low prevalence of diabetes mellitus in TB patients and the community in urban Uganda.
    Int J Tuberc Lung Dis. 2021;25:590-592.
    >> Share

  355. DOUGLAS-JONES B, Mohr-Holland E, Mema N, Mathee S, et al
    A home-based care programme for rifampicin-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:587-589.
    >> Share

  356. HABIB SS, Malik AA, Khan U, Khowaja S, et al
    Impact of upfront Xpert testing on time to treatment initiation for multidrug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:584-586.
    >> Share

  357. MORAN A, Lebona L, Makgopa G, Nkwane Y, et al
    One size does not fit all: reaching agricultural workers in South Africa with TB services.
    Int J Tuberc Lung Dis. 2021;25:573-578.
    >> Share

  358. YANGTHARA B, Wutthigate P, Roongmaitree S, Siripattanapipong P, et al
    Nosocomial TB in two neonatal intensive care units at a tertiary care centre: infection risk and outcomes.
    Int J Tuberc Lung Dis. 2021;25:567-572.
    >> Share

  359. BLACK DA, McBrien SW, Gersh J, Ghassemieh B, et al
    TB risk by time since U.S. entry among non-U.S.-born residents of Washington State, USA.
    Int J Tuberc Lung Dis. 2021;25:560-566.
    >> Share

  360. FEUTH T, Patovirta RL, Grierson S, Danilovits M, et al
    Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines.
    Int J Tuberc Lung Dis. 2021;25:554-559.
    >> Share

  361. LARGEN A, Ayala A, Khurana R, Katz DJ, et al
    Evaluation of point-of-care algorithms to detect diabetes during screening for latent TB infection.
    Int J Tuberc Lung Dis. 2021;25:547-553.
    >> Share

  362. BALUKU JB, Nuwagira E, Bongomin F, Denning DW, et al
    Pulmonary TB and chronic pulmonary aspergillosis: clinical differences and similarities.
    Int J Tuberc Lung Dis. 2021;25:537-546.
    >> Share

  363. SHARMA M, Onozaki I, Nunn P
    TB in older people in Asia: why it is important.
    Int J Tuberc Lung Dis. 2021;25:521-524.
    >> Share

  364. SALZER HJF, Wang JY
    Chronic pulmonary aspergillosis as a sequel to pulmonary TB.
    Int J Tuberc Lung Dis. 2021;25:519-520.
    >> Share

    June 2021
  365. AGOSTINIS A, Heffernan C, Long R, Beckon A, et al
    Interferon-gamma release assays for latent tuberculosis infection screening in Canadian federal correctional facilities.
    Int J Tuberc Lung Dis. 2021;25:447-452.
    >> Share

  366. TEO AKJ, Ong CWM, Hsu LY
    COVID-19 and TB: a progression-regression conundrum.
    Int J Tuberc Lung Dis. 2021;25:421-423.
    >> Share

  367. BASHAM CA, Romanowski K, Johnston JC
    Alcohol use disorder and TB survivor health.
    Int J Tuberc Lung Dis. 2021;25:516-517.
    >> Share

  368. MANTSHONYANE L, Kgwaadira B, Gross R
    The absence of evidence of cure is not a risk for recurrent TB among patients treated for TB.
    Int J Tuberc Lung Dis. 2021;25:511-512.
    >> Share

  369. ROYCROFT E, Fitzgibbon MM, Kelly DM, Scully M, et al
    The largest prison outbreak of TB in Western Europe investigated using whole-genome sequencing.
    Int J Tuberc Lung Dis. 2021;25:491-497.
    >> Share

  370. SZKWARKO D, Amisi JA, Peterson D, Burudi S, et al
    Using a mobile application to improve pediatric presumptive TB identification in western Kenya.
    Int J Tuberc Lung Dis. 2021;25:468-474.
    >> Share

  371. REDWOOD L, Mitchell EMH, Viney K, Snow K, et al
    Depression, stigma and quality of life in people with drug-susceptible TB and drug-resistant TB in Vietnam.
    Int J Tuberc Lung Dis. 2021;25:461-467.
    >> Share

  372. OELOFSE S, Esmail A, Diacon AH, Conradie F, et al
    Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
    Int J Tuberc Lung Dis. 2021;25:453-460.
    >> Share

  373. CHAISSON LH, Naufal F, Delgado-Barroso P, Alvarez-Manzo HS, et al
    A systematic review of the number needed to screen for active TB among people living with HIV.
    Int J Tuberc Lung Dis. 2021;25:427-435.
    >> Share

  374. TAVOSCHI L, Toscanini F, Pontali E
    TB and prisons: confinement does not contain the disease.
    Int J Tuberc Lung Dis. 2021;25:424-426.
    >> Share

  375. AKKERMAN OW, Tiberi S, Alffenaar JW
    Shortening MDR-TB treatment: is treating more patients with fewer drugs better?
    Int J Tuberc Lung Dis. 2021;25:419-420.
    >> Share

    May 2021
  376. ZOKUFA N, Lebelo K, Hacking D, Tabo L, et al
    Community-based TB testing as an essential part of TB recovery plans in the COVID-19 era.
    Int J Tuberc Lung Dis. 2021;25:406-408.
    >> Share

  377. POLLOCK NR, MacIntyre AT, Blauwkamp TA, Blair L, et al
    Detection of Mycobacterium tuberculosis cell-free DNA to diagnose TB in pediatric and adult patients.
    Int J Tuberc Lung Dis. 2021;25:403-405.
    >> Share

  378. MIN J, Kang JY, Kim J, Yang J, et al
    Impact of COVID-19 on TB services in Korea.
    Int J Tuberc Lung Dis. 2021;25:400-402.
    >> Share

  379. MARGINEANU I, Mor Z, Garcia D, Gilpin C, et al
    TB and COVID-19 in migrants - the need to focus on both conditions.
    Int J Tuberc Lung Dis. 2021;25:333-335.
    >> Share

  380. MCQUAID CF, Foster N, Quaife M, Levy J, et al
    Digital adherence technology for TB: focus on livelihoods as well as lives.
    Int J Tuberc Lung Dis. 2021;25:416-417.
    >> Share

  381. RICCARDI N, Saderi L, Borroni E, Tagliani E, et al
    Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study.
    Int J Tuberc Lung Dis. 2021;25:395-399.
    >> Share

  382. KALEMA N, Semeere A, Banturaki G, Kyamugabwa A, et al
    Gaps in TB preventive therapy for persons initiating antiretroviral therapy in Uganda: an explanatory sequential cascade analysis.
    Int J Tuberc Lung Dis. 2021;25:388-394.
    >> Share

  383. SATYANARAYANA S, Bhatia V, Mandal PP, Kanchar A, et al
    Urgent need to address the slow scale-up of TB preventive treatment in the WHO South-East Asia Region.
    Int J Tuberc Lung Dis. 2021;25:382-387.
    >> Share

  384. FERREIRO L, Ruano-Ravina A, Otero-Mallo R, Pou-Alvarez C, et al
    Recent epidemiological trends in extrapulmonary TB in Galicia, Spain.
    Int J Tuberc Lung Dis. 2021;25:373-381.
    >> Share

  385. WEYENGA H, Karanja M, Onyango E, Katana AK, et al
    Can isoniazid preventive therapy be scaled up rapidly? Lessons learned in Kenya, 2014-2018.
    Int J Tuberc Lung Dis. 2021;25:367-372.
    >> Share

  386. MARTSON AG, Kim HY, Marais B, Alffenaar JW, et al
    The importance of pharmacokinetics/pharmacodynamics assessment in Phase IIB/III trials for MDR-TB treatment.
    Int J Tuberc Lung Dis. 2021;25:336-339.
    >> Share

    April 2021
  387. MALABAD JCM, Ang CF, Palabrica FAR, Cajucom MAM, et al
    Molecular epidemiology of Mycobacterium tuberculosis in adult Filipino TB-HIV co-infected patients.
    Int J Tuberc Lung Dis. 2021;25:285-291.
    >> Share

  388. HARRIES AD, Kumar AMV, Satyanarayana S, Thekkur P, et al
    TB and COVID-19: measuring key risk factors that affect treatment outcomes.
    Int J Tuberc Lung Dis. 2021;25:329-331.
    >> Share

  389. COX V, Guglielmetti L, Hewison C, Reuter A, et al
    Reply to: "Human rights: finding the right balance for rifampicin-resistant TB treatment".
    Int J Tuberc Lung Dis. 2021;25:328-329.
    >> Share

  390. VAN DEUN A, Piubello A, Lynen L, de Jong BC, et al
    Human rights: finding the right balance for rifampicin-resistant TB treatment.
    Int J Tuberc Lung Dis. 2021;25:327-328.
    >> Share

  391. GULLON-BLANCO JA, Rodrigo-Sanz T, Alvarez-Navascues F, Tabernero-Huguet E, et al
    Completion of treatment for latent TB infection in a low prevalence setting.
    Int J Tuberc Lung Dis. 2021;25:321-323.
    >> Share

  392. ROY N, Krishnamoorthy Y, Rajaa S, Ezhumalai K, et al
    Health-related quality of life and its effect on TB treatment outcomes.
    Int J Tuberc Lung Dis. 2021;25:318-320.
    >> Share

  393. BHERING M, Duarte R, Kritski A
    Treatment outcomes and predictive factors for multidrug-resistant TB and HIV coinfection in Rio de Janeiro State, Brazil.
    Int J Tuberc Lung Dis. 2021;25:292-298.
    >> Share

  394. CHESOV D, Butov D, Reimann M, Heyckendorf J, et al
    Impact of lung function on treatment outcome in patients with TB.
    Int J Tuberc Lung Dis. 2021;25:277-284.
    >> Share

  395. VISCA D, D Ambrosio L, Centis R, Pontali E, et al
    Post-TB disease: a new topic for investigation-and why it matters.
    Int J Tuberc Lung Dis. 2021;25:258-261.
    >> Share

  396. LAU A, Ferrara G
    Disseminated TB: still being missed and misunderstood.
    Int J Tuberc Lung Dis. 2021;25:255-257.
    >> Share

  397. SCHULTINK MP, Kerstjens HAM, Ter Beek L, Zondag H, et al
    Assessment of TB treatment on patient well-being.
    Int J Tuberc Lung Dis. 2021;25:315-317.
    >> Share

    March 2021
  398. KUMAR MS, Surendran D, Manu MS, Rakesh PS, et al
    Mortality due to TB-COVID-19 coinfection in India.
    Int J Tuberc Lung Dis. 2021;25:250-251.
    >> Share

  399. GRACIAA DS, Kempker RR, Sanikidze E, Tukvadze S, et al
    TB research amidst the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2021;25:167-170.
    >> Share

  400. ALLWOOD BW, van der Zalm MM, Mortimer K
    Reply to "Clinical care for patients with post TB lung disease".
    Int J Tuberc Lung Dis. 2021;25:253-254.
    >> Share

  401. GUNTHER G, Ithete S
    Clinical care for patients with post-TB lung disease.
    Int J Tuberc Lung Dis. 2021;25:252-253.
    >> Share

  402. PARK JH, Jung J, Kim JY, Hong MJ, et al
    Airborne precautions based on Xpert((R)) MTB/RIF results for patients with presumptive TB.
    Int J Tuberc Lung Dis. 2021;25:244-246.
    >> Share

  403. KIZNY GORDON A, Tong SYC, Martinez E, Crighton T, et al
    TB genomic surveillance and data sharing in recognising contamination events.
    Int J Tuberc Lung Dis. 2021;25:241-243.
    >> Share

  404. BAIK Y, Nalutaaya A, Kitonsa PJ, Dowdy DW, et al
    Infection status of contacts is not associated with severity of TB in the index case.
    Int J Tuberc Lung Dis. 2021;25:237-240.
    >> Share

  405. ADANKWAH E, Arthur RA, Minadzi D, Owusu DO, et al
    Immune response against TB and non-tuberculous mycobacterial pulmonary disease.
    Int J Tuberc Lung Dis. 2021;25:234-236.
    >> Share

  406. MALIK AA, Fuad J, Abbass W, Ikhlaque S, et al
    Preventive treatment of drug-resistant TB in a rural setting.
    Int J Tuberc Lung Dis. 2021;25:231-233.
    >> Share

  407. CATES L, Crudu V, Codreanu A, Ciobanu N, et al
    Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting.
    Int J Tuberc Lung Dis. 2021;25:228-230.
    >> Share

  408. COX SR, Gupte AN, Thomas B, Gaikwad S, et al
    Unhealthy alcohol use independently associated with unfavorable TB treatment outcomes among Indian men.
    Int J Tuberc Lung Dis. 2021;25:182-190.
    >> Share

  409. SOHN H, Sweeney S, Mudzengi D, Creswell J, et al
    Determining the value of TB active case-finding: current evidence and methodological considerations.
    Int J Tuberc Lung Dis. 2021;25:171-181.
    >> Share

    February 2021
  410. BARRETT J, Painter H, Rajgopal A, Keane D, et al
    Increase in disseminated TB during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2021;25:160-166.
    >> Share

  411. ALLWOOD BW, van der Zalm MM, Mortimer K
    Reply to: Taking action to improve post-TB lung health.
    Int J Tuberc Lung Dis. 2021;25:163a-163.
    >> Share

  412. HARRIES AD, Dlodlo RA, Brigden G, Chakaya JM, et al
    Taking action to improve post-TB lung health.
    Int J Tuberc Lung Dis. 2021;25:161-162.
    >> Share

  413. MOLINA-MOYA B, Guglielmetti L, Bothamley G, van Leth F, et al
    Use and impact of molecular methods for detecting drug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:157-159.
    >> Share

  414. LAW WS, Chan CKA, Leung CC
    Management of latent TB infection in child household contacts aged under 5 years.
    Int J Tuberc Lung Dis. 2021;25:151-153.
    >> Share

  415. MEHTA SN, Murrill M, Suryavanshi N, Bhosale R, et al
    TB-related knowledge and stigma among pregnant women in low-resource settings.
    Int J Tuberc Lung Dis. 2021;25:148-150.
    >> Share

  416. ARSCOTT-MILLS T, Ejelonu A, Mokalane K, Machao G, et al
    One third of child TB cases were missing from the national TB register in Botswana.
    Int J Tuberc Lung Dis. 2021;25:142-144.
    >> Share

  417. DE VOS E, Scott L, Voss De Lima Y, Warren RM, et al
    Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa.
    Int J Tuberc Lung Dis. 2021;25:134-141.
    >> Share

  418. SOTGIU G, Rosales-Klintz S, Centis R, D'Ambrosio L, et al
    TB management in the European Union/European Economic Area: a multi-centre survey.
    Int J Tuberc Lung Dis. 2021;25:126-133.
    >> Share

  419. FOX GJ, Johnston JC, Nguyen TA, Majumdar SS, et al
    Active case-finding in contacts of people with TB.
    Int J Tuberc Lung Dis. 2021;25:95-105.
    >> Share

  420. LINH NN, Miller C, Marks GB
    Potential benefits of active case finding to reduce the burden of TB.
    Int J Tuberc Lung Dis. 2021;25:93-94.
    >> Share

    January 2021
  421. SHEN X, Sha W, Yang C, Pan Q, et al
    Continuity of TB services during the COVID-19 pandemic in China.
    Int J Tuberc Lung Dis. 2021;25:81-83.
    >> Share


  422. TB and COVID-19 co-infection: rationale and aims of a global study.
    Int J Tuberc Lung Dis. 2021;25:78-80.
    >> Share

  423. MAUG AKJ, Hossain MA, Gumusboga M, Decroo T, et al
    Finding the right balance between efficacy and tolerability for TB treatment: the search continues.
    Int J Tuberc Lung Dis. 2021;25:84-86.
    >> Share

  424. PARIGI S, Venturini E, Galli L, Chiappini E, et al
    Xpert((R)) MTB/RIF Ultra performance in diagnosing paediatric pulmonary TB in gastric aspirates.
    Int J Tuberc Lung Dis. 2021;25:75-77.
    >> Share

  425. SAKR CJ, Musharrafieh UM, Banna HS, Hoteit RA, et al
    Risks and benefits of QuantiFERON((R))-TB testing for LTBI screening of health workers.
    Int J Tuberc Lung Dis. 2021;25:72-74.
    >> Share

  426. GENDERINI FG, Dauby N, Delforge M, De Wit S, et al
    TB in the intensive care unit in a low-endemic country.
    Int J Tuberc Lung Dis. 2021;25:69-71.
    >> Share

  427. NABISERE R, Arinaitwe A, Muyise R, Asienzo J, et al
    Implementation of TB preventive therapy in Uganda: effect of an intervention on completion rates.
    Int J Tuberc Lung Dis. 2021;25:64-65.
    >> Share

  428. TUCKER A, Oyuku D, Nalugwa T, Nantale M, et al
    Costs along the TB diagnostic pathway in Uganda.
    Int J Tuberc Lung Dis. 2021;25:61-63.
    >> Share

  429. MAVE V, Kadam D, Gaikwad S, Kinikar A, et al
    Measuring TB drug levels in the hair in adults and children to monitor drug exposure and outcomes.
    Int J Tuberc Lung Dis. 2021;25:52-60.
    >> Share

  430. MESFIN AB, Araia ZZ, Beyene HN, Mebrahtu AH, et al
    First molecular-based anti-TB drug resistance survey in Eritrea.
    Int J Tuberc Lung Dis. 2021;25:43-51.
    >> Share

  431. SENEADZA NAH, Antwi S, Yang H, Enimil A, et al
    Effect of malnutrition on the pharmacokinetics of anti-TB drugs in Ghanaian children.
    Int J Tuberc Lung Dis. 2021;25:36-42.
    >> Share

  432. WROHAN I, Redwood L, Ho J, Velen K, et al
    Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.
    Int J Tuberc Lung Dis. 2021;25:23-30.
    >> Share

  433. SOH AZ, Tan CTY, Mok E, Chee CBE, et al
    Adipokines and the risk of active TB: a nested case-control study.
    Int J Tuberc Lung Dis. 2021;25:31-35.
    >> Share

    December 2020
  434. ZHANG H, Cao X, Wang D, Xin H, et al
    The acquisition of Mycobacterium tuberculosis infection in village doctors in China: a prospective study.
    Int J Tuberc Lung Dis. 2020;24:1241-1246.
    >> Share

  435. FANG JL, Chao CM, Tang HJ
    The impact of COVID-19 on the diagnosis of TB in Taiwan.
    Int J Tuberc Lung Dis. 2020;24:1321-1322.
    >> Share

  436. SINGH J, Ehtesham NZ, Hasnain SE
    Two parallel pandemics: the challenges faced by countries with COVID-19 and TB.
    Int J Tuberc Lung Dis. 2020;24:1319-1320.
    >> Share

    November 2020
  437. FATIMA R, Yaqoob A
    In Reply: How TB and COVID-19 compare: an opportunity to integrate both control programmes.
    Int J Tuberc Lung Dis. 2020;24:1227-1228.
    >> Share

  438. DE SOUZA CDF, Coutinho HS, Costa MM, Magalhaes MAFM, et al
    Impact of COVID-19 on TB diagnosis in Northeastern Brazil.
    Int J Tuberc Lung Dis. 2020;24:1220-1222.
    >> Share

  439. ZHOU S, Van Staden Q, Toska E
    Resource reprioritisation amid competing health risks for TB and COVID-19.
    Int J Tuberc Lung Dis. 2020;24:1215-1216.
    >> Share

  440. KADOTA JL, Reza TF, Nalugwa T, Kityamuwesi A, et al
    Impact of shelter-in-place on TB case notifications and mortality during the COVID-19 pandemic.
    Int J Tuberc Lung Dis. 2020;24:1212-1214.
    >> Share

  441. HAAS MK, Ignatius EH, Stout JE, Dooley KE, et al
    Finding the right balance between efficacy and tolerability for TB treatment.
    Int J Tuberc Lung Dis. 2020;24:1225b-1226.
    >> Share

  442. WANG EY, Ahluwalia IB, Mase SR
    Response to Correspondence: The impact of smoking on TB treatment outcomes includes recurrent TB.
    Int J Tuberc Lung Dis. 2020;24:1225a-1225.
    >> Share

  443. DHAMGAYE TM
    In reply: Latent TB treatment in pregnant women: a patient perspective.
    Int J Tuberc Lung Dis. 2020;24:1226-1227.
    >> Share

  444. CHIANG CY, Bam TS
    The impact of smoking on TB treatment outcomes includes recurrent TB.
    Int J Tuberc Lung Dis. 2020;24:1224-1225.
    >> Share

    October 2020
  445. KIM HW, Min J, Shin AY, Koo HK, et al
    Reasons why patients with tuberculosis in South Korea stop anti-TB treatment: a cross-sectional study.
    Int J Tuberc Lung Dis. 2020;24:1016-1023.
    >> Share

  446. SHAHRIARIRAD R, Fallahi MJ
    TB and the COVID-19 pandemic: brothers in arms against lung health.
    Int J Tuberc Lung Dis. 2020;24:1126-1127.
    >> Share

  447. WU Z, Chen J, Xia Z, Pan Q, et al
    Impact of the COVID-19 pandemic on the detection of TB in Shanghai, China.
    Int J Tuberc Lung Dis. 2020;24:1122-1124.
    >> Share

  448. MENEGUIM AC, Rebello L, Das M, Ravi S, et al
    Adapting TB services during the COVID-19 pandemic in Mumbai, India.
    Int J Tuberc Lung Dis. 2020;24:1119-1121.
    >> Share

  449. HELDAL E, Dlodlo RA
    Estimating subnational TB burden-why not strengthen and use routine recording and reporting?
    Int J Tuberc Lung Dis. 2020;24:1125-1127.
    >> Share

  450. AKKERMAN OW, Tiberi S
    The importance of knowing why TB patients stop anti-TB treatment.
    Int J Tuberc Lung Dis. 2020;24:989-990.
    >> Share

    September 2020
  451. YASSIN M, Grzemska M
    Response to 'The Green Light Committee could contribute to ending tuberculosis .
    Int J Tuberc Lung Dis. 2020;24:984.
    >> Share

  452. NGUYEN TBP, Nguyen TA, Luu BK, Le TTO, et al
    A comparison of digital chest radiography and Xpert((R)) MTB/RIF in active case finding for tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:934-940.
    >> Share

  453. CHIANG CH, Lee GH, Chiang TH, Tang PU, et al
    Disseminated Mycobacterium avium complex infection as a differential diagnosis of tuberculosis in HIV patients.
    Int J Tuberc Lung Dis. 2020;24:922-927.
    >> Share

  454. LOVEDAY M, Hlangu S, Furin J
    Breastfeeding in women living with tuberculosis.
    Int J Tuberc Lung Dis. 2020;24:880-891.
    >> Share

  455. ADEWOLE OO
    Impact of COVID-19 on TB care: experiences of a treatment centre in Nigeria.
    Int J Tuberc Lung Dis. 2020;24:981-982.
    >> Share

  456. VAN DER WALT M, Keddy KH
    How COVID-19 can instruct TB research: ensuring the safety of researchers exposed to infectious disease.
    Int J Tuberc Lung Dis. 2020;24:978-980.
    >> Share

  457. WILSON FA, Miller TL, Stimpson JP
    COVID-19 and TB control in immigrant communities.
    Int J Tuberc Lung Dis. 2020;24:975-977.
    >> Share

  458. ECHEVERRIA G, Espinoza W, de Waard JH
    How TB and COVID-19 compare: an opportunity to integrate both control programmes.
    Int J Tuberc Lung Dis. 2020;24:971-974.
    >> Share

  459. MULDER C, Nkiligi E, Kondo Z, Scholten JN, et al
    What to look for when using SUBsET for subnational TB incidence estimates.
    Int J Tuberc Lung Dis. 2020;24:983-984.
    >> Share

  460. WANG J, Garcia-Basteiro AL
    Should vitamin D supplementation be used concomitantly with LTBI treatment?
    Int J Tuberc Lung Dis. 2020;24:875-876.
    >> Share

    August 2020
  461. CHIANG CY
    Green Light Committee and WHO recommendations.
    Int J Tuberc Lung Dis. 2020;24:873-874.
    >> Share

    June 2020
  462. HARRIES AD
    In Response to Reinout van Crevel et al.
    Int J Tuberc Lung Dis. 2020;24:634.
    >> Share

    May 2020
  463. FURIN J
    Can Green Light Committees help "end TB"?
    Int J Tuberc Lung Dis. 2020;24:540.
    >> Share

    April 2020
  464. BASHAM CA, Romanowski K, Johnston JC
    Cardiovascular disease: the forgotten cousin of post-TB health?
    Int J Tuberc Lung Dis. 2020;24:466-467.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016